| Year |
Citation |
Score |
| 2024 |
Casalin I, De Stefano A, Ceneri E, Cappellini A, Finelli C, Curti A, Paolini S, Parisi S, Zannoni L, Boultwood J, McCubrey JA, Suh PG, Ramazzotti G, Fiume R, Ratti S, et al. Deciphering signaling pathways in hematopoietic stem cells: the molecular complexity of Myelodysplastic Syndromes (MDS) and leukemic progression. Advances in Biological Regulation. 101014. PMID 38242820 DOI: 10.1016/j.jbior.2024.101014 |
0.306 |
|
| 2023 |
Martelli AM, Paganelli F, Truocchio S, Palumbo C, Chiarini F, McCubrey JA. Understanding the Roles of the Hedgehog Signaling Pathway during T-Cell Lymphopoiesis and in T-Cell Acute Lymphoblastic Leukemia (T-ALL). International Journal of Molecular Sciences. 24. PMID 36769284 DOI: 10.3390/ijms24032962 |
0.331 |
|
| 2023 |
De Stefano A, Marvi MV, Fazio A, McCubrey JA, Suh PG, Ratti S, Ramazzotti G, Manzoli L, Cocco L, Follo MY. Advances in MDS/AML and inositide signalling. Advances in Biological Regulation. 87: 100955. PMID 36706610 DOI: 10.1016/j.jbior.2023.100955 |
0.365 |
|
| 2022 |
McCubrey JA, Abrams SL, Follo MY, Manzoli L, Ratti S, Martelli AM, Cervello M. Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies. Advances in Biological Regulation. 100917. PMID 36243652 DOI: 10.1016/j.jbior.2022.100917 |
0.341 |
|
| 2022 |
Martelli AM, Paganelli F, Evangelisti C, Chiarini F, McCubrey JA. Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies. Cells. 11. PMID 35681507 DOI: 10.3390/cells11111812 |
0.394 |
|
| 2022 |
McCubrey JA, Meher AK, Akula SM, Abrams SL, Steelman LS, LaHair MM, Franklin RA, Martelli AM, Ratti S, Cocco L, Barbaro F, Duda P, Gizak A. Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties. Aging. 14: 3365-3386. PMID 35477123 DOI: 10.18632/aging.204038 |
0.399 |
|
| 2022 |
Abrams SL, Duda P, Akula SM, Steelman LS, Follo ML, Cocco L, Ratti S, Martelli AM, Montalto G, Emma MR, Cervello M, Rakus D, Gizak A, McCubrey JA. Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53. Cells. 11. PMID 35269416 DOI: 10.3390/cells11050794 |
0.311 |
|
| 2021 |
Abrams SL, Akula SM, Steelman LS, Follo ML, Cocco L, Ratti S, Martelli AM, Libra M, Falzone L, Candido S, Montalto G, Cervello M, Lombardi P, McCubrey JA. Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53. Advances in Biological Regulation. 83: 100840. PMID 34866036 DOI: 10.1016/j.jbior.2021.100840 |
0.333 |
|
| 2021 |
Basile MS, Cavalli E, McCubrey J, Hernández-Bello J, Muñoz-Valle JF, Fagone P, Nicoletti F. The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19. Drug Discovery Today. 27: 848-856. PMID 34763066 DOI: 10.1016/j.drudis.2021.11.002 |
0.405 |
|
| 2021 |
Hajka D, Budziak B, Pietras Ł, Duda P, McCubrey JA, Gizak A. GSK3 as a Regulator of Cytoskeleton Architecture: Consequences for Health and Disease. Cells. 10. PMID 34440861 DOI: 10.3390/cells10082092 |
0.341 |
|
| 2021 |
Abrams SL, Akula SM, Meher AK, Steelman LS, Gizak A, Duda P, Rakus D, Martelli AM, Ratti S, Cocco L, Montalto G, Cervello M, Ruvolo P, Libra M, Falzone L, ... ... McCubrey JA, et al. GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. Cells. 10. PMID 33917370 DOI: 10.3390/cells10040816 |
0.339 |
|
| 2021 |
Martelli AM, Evangelisti C, Paganelli F, Chiarini F, McCubrey JA. GSK-3: a multifaceted player in acute leukemias. Leukemia. PMID 33811246 DOI: 10.1038/s41375-021-01243-z |
0.431 |
|
| 2021 |
Abrams SL, Akula SM, Martelli AM, Cocco L, Ratti S, Libra M, Candido S, Montalto G, Cervello M, Gizak A, Rakus D, Steelman LS, McCubrey JA. Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53. Advances in Biological Regulation. 100780. PMID 33451973 DOI: 10.1016/j.jbior.2020.100780 |
0.335 |
|
| 2020 |
Steelman LS, Chappell WH, Akula SM, Abrams SL, Cocco L, Manzoli L, Ratti S, Martelli AM, Montalto G, Cervello M, Libra M, Candido S, McCubrey JA. Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling. Advances in Biological Regulation. 78: 100758. PMID 33022466 DOI: 10.1016/j.jbior.2020.100758 |
0.365 |
|
| 2020 |
Cappellini A, Mongiorgi S, Finelli C, Fazio A, Ratti S, Marvi MV, Curti A, Salvestrini V, Pellagatti A, Billi AM, Suh PG, McCubrey JA, Boultwood J, Manzoli L, Cocco L, et al. Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS). Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 32959428 DOI: 10.1096/Fj.202000933Rr |
0.394 |
|
| 2020 |
Akula SM, Abrams SL, Steelman LS, Candido S, Libra M, Lerpiriyapong K, Cocco L, Ramazzotti G, Ratti S, Follo MY, Martelli AM, Blalock WL, Piazzi M, Montalto G, Cervello M, ... ... McCubrey JA, et al. Cancer therapy and treatments during COVID-19 era. Advances in Biological Regulation. 77: 100739. PMID 32773105 DOI: 10.1016/J.Jbior.2020.100739 |
0.612 |
|
| 2020 |
Fazio A, Owusu Obeng E, Rusciano I, Marvi MV, Zoli M, Mongiorgi S, Ramazzotti G, Follo MY, McCubrey JA, Cocco L, Manzoli L, Ratti S. Subcellular Localization Relevance and Cancer-Associated Mechanisms of Diacylglycerol Kinases. International Journal of Molecular Sciences. 21. PMID 32722576 DOI: 10.3390/Ijms21155297 |
0.46 |
|
| 2020 |
Augello G, Emma MR, Cusimano A, Azzolina A, Montalto G, McCubrey JA, Cervello M. The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment. Cells. 9. PMID 32526891 DOI: 10.3390/Cells9061427 |
0.454 |
|
| 2020 |
Duda P, Akula SM, Abrams SL, Steelman LS, Gizak A, Rakus D, McCubrey JA. GSK-3 and miRs: Master regulators of therapeutic sensitivity of cancer cells. Biochimica Et Biophysica Acta. Molecular Cell Research. 1867: 118770. PMID 32524999 DOI: 10.1016/J.Bbamcr.2020.118770 |
0.509 |
|
| 2020 |
Alfhili MA, Alsughayyir JM, McCubrey JA, Akula SM. GSK-3-associated signaling is crucial to virus infection of cells. Biochimica Et Biophysica Acta. Molecular Cell Research. 118767. PMID 32522661 DOI: 10.1016/J.Bbamcr.2020.118767 |
0.425 |
|
| 2020 |
Emma MR, Augello G, Cusimano A, Azzolina A, Montalto G, McCubrey JA, Cervello M. GSK-3 in liver diseases: Friend or foe? Biochimica Et Biophysica Acta. Molecular Cell Research. 118743. PMID 32417256 DOI: 10.1016/J.Bbamcr.2020.118743 |
0.305 |
|
| 2020 |
Duda P, Akula SM, Abrams SL, Steelman LS, Martelli AM, Cocco L, Ratti S, Candido S, Libra M, Montalto G, Cervello M, Gizak A, Rakus D, McCubrey JA. Targeting GSK3 and Associated Signaling Pathways Involved in Cancer. Cells. 9. PMID 32365809 DOI: 10.3390/Cells9051110 |
0.491 |
|
| 2020 |
Martelli AM, Paganelli F, Chiarini F, Evangelisti C, McCubrey JA. The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias. Cancers. 12. PMID 32024211 DOI: 10.3390/Cancers12020333 |
0.454 |
|
| 2020 |
Duda P, Janczara J, McCubrey JA, Gizak A, Rakus D. The Reverse Warburg Effect is Associated with Fbp2-Dependent Hif1α Regulation in Cancer Cells Stimulated by Fibroblasts. Cells. 9. PMID 31947613 DOI: 10.3390/Cells9010205 |
0.404 |
|
| 2020 |
Akula SM, Abrams SL, Steelman LS, Candido S, Libra M, Lerpiriyapong K, Cocco L, Ramazzotti G, Ratti S, Follo MY, Martelli AM, Blalock WL, Piazzi M, Montalto G, Cervello M, ... ... McCubrey JA, et al. Cancer therapy and treatments during COVID-19 era Advances in Biological Regulation. 77: 100739. DOI: 10.1016/j.jbior.2020.100739 |
0.567 |
|
| 2019 |
Follo MY, Ratti S, Manzoli L, Ramazzotti G, Faenza I, Fiume R, Mongiorgi S, Suh PG, McCubrey JA, Cocco L. Inositide-Dependent Nuclear Signalling in Health and Disease. Handbook of Experimental Pharmacology. PMID 31889219 DOI: 10.1007/164_2019_321 |
0.384 |
|
| 2019 |
Follo MY, Pellagatti A, Ratti S, Ramazzotti G, Faenza I, Fiume R, Mongiorgi S, Suh PG, McCubrey JA, Manzoli L, Boultwood J, Cocco L. Recent advances in MDS mutation landscape: Splicing and signalling. Advances in Biological Regulation. 100673. PMID 31711974 DOI: 10.1016/J.Jbior.2019.100673 |
0.34 |
|
| 2019 |
Akula SM, Candido S, Abrams SL, Steelman LS, Lertpiriyapong K, Cocco L, Ramazzotti G, Ratti S, Follo MY, Martelli AM, Murata RM, Rosalen PL, Bueno-Silva B, Matias de Alencar S, Falasca M, ... ... McCubrey JA, et al. Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells. Advances in Biological Regulation. 100672. PMID 31685431 DOI: 10.1016/J.Jbior.2019.100672 |
0.425 |
|
| 2019 |
Akula SM, Abrams SL, Steelman LS, Emma MR, Augello G, Cusimano A, Azzolina A, Montalto G, Cervello M, McCubrey JA. RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma. Expert Opinion On Therapeutic Targets. 1-15. PMID 31657972 DOI: 10.1080/14728222.2019.1685501 |
0.379 |
|
| 2019 |
Poma P, Labbozzetta M, McCubrey JA, Ramarosandratana AV, Sajeva M, Zito P, Notarbartolo M. Antitumor Mechanism of the Essential Oils from Two Succulent Plants in Multidrug Resistance Leukemia Cell. Pharmaceuticals (Basel, Switzerland). 12. PMID 31454963 DOI: 10.3390/Ph12030124 |
0.321 |
|
| 2019 |
Martelli AM, Paganelli F, Fazio A, Bazzichetto C, Conciatori F, McCubrey JA. The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response. Cancers. 11. PMID 31064074 DOI: 10.3390/Cancers11050629 |
0.382 |
|
| 2019 |
Akula SM, Candido S, Libra M, Abrams SL, Steelman LS, Lertpiriyapong K, Ramazzotti G, Ratti S, Follo MY, Martelli AM, Murata RM, Rosalen PL, Bueno-Silva B, Matias de Alencar S, Montalto G, ... ... McCubrey JA, et al. Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. Advances in Biological Regulation. PMID 31047842 DOI: 10.1016/J.Jbior.2019.04.003 |
0.4 |
|
| 2019 |
Charini F, Evangelisti C, Lattanzi G, McCubrey JA, Martelli AM. Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. Biochimica Et Biophysica Acta. Molecular Cell Research. PMID 30928610 DOI: 10.1016/J.Bbamcr.2019.03.013 |
0.501 |
|
| 2019 |
Candido S, Abrams SL, Steelman LS, Lertpiriyapong K, Martelli AM, Cocco L, Ratti S, Follo MY, Murata RM, Rosalen PL, Bueno-Silva B, de Alencar SM, Lombardi P, Mao W, Montalto G, ... ... McCubrey JA, et al. Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals. Advances in Biological Regulation. PMID 30898612 DOI: 10.1016/J.Jbior.2019.03.002 |
0.423 |
|
| 2018 |
Bertacchini J, Mediani L, Beretti F, Guida M, Ghalali A, Brugnoli F, Bertagnolo V, Petricoin E, Poti F, Arioli J, Anselmi L, Bari A, McCubrey J, Martelli AM, Cocco L, et al. Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit. Journal of Cellular Physiology. PMID 30565691 DOI: 10.1002/Jcp.27768 |
0.441 |
|
| 2018 |
Ramazzotti G, Fiume R, Chiarini F, Campana G, Ratti S, Billi AM, Manzoli L, Follo MY, Suh PG, McCubrey J, Cocco L, Faenza I. Phospholipase C-β1 interacts with cyclin E in adipose- derived stem cells osteogenic differentiation. Advances in Biological Regulation. PMID 30420274 DOI: 10.1016/J.Jbior.2018.11.001 |
0.392 |
|
| 2018 |
Abrams SL, Follo MY, Steelman LS, Lertpiriyapong K, Cocco L, Ratti S, Martelli AM, Candido S, Libra M, Murata RM, Rosalen PL, Montalto G, Cervello M, Gizak A, Rakus D, ... ... McCubrey JA, et al. Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. Advances in Biological Regulation. PMID 30361003 DOI: 10.1016/J.Jbior.2018.10.003 |
0.378 |
|
| 2018 |
Ratti S, Follo MY, Ramazzotti G, Faenza I, Fiume R, Suh PG, McCubrey JA, Manzoli L, Cocco L. Nuclear Phospholipase C isoenzyme imbalance leads to pathologies in brain, hematologic, neuromuscular and fertility disorders. Journal of Lipid Research. PMID 30287524 DOI: 10.1194/Jlr.R089763 |
0.38 |
|
| 2018 |
Duda P, Wiśniewski J, Wójtowicz T, Wójcicka O, Jaśkiewicz M, Drulis-Fajdasz D, Rakus D, McCubrey JA, Gizak A. Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging. Expert Opinion On Therapeutic Targets. 1-16. PMID 30244615 DOI: 10.1080/14728222.2018.1526925 |
0.377 |
|
| 2018 |
Leontovich AA, Jalalirad M, Salisbury JL, Mills L, Haddox C, Schroeder M, Tuma A, Guicciardi ME, Zammataro L, Gambino MW, Amato A, Di Leonardo A, McCubrey J, Lange CA, Liu M, et al. NOTCH3 expression is linked to breast cancer seeding and distant metastasis. Breast Cancer Research : Bcr. 20: 105. PMID 30180881 DOI: 10.1186/S13058-018-1020-0 |
0.353 |
|
| 2018 |
Abrams SL, Lertpiriyapong K, Yang LV, Martelli AM, Cocco L, Ratti S, Falasca M, Murata RM, Rosalen PL, Lombardi P, Libra M, Candido S, Montalto G, Cervello M, Steelman LS, ... McCubrey JA, et al. Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. Advances in Biological Regulation. PMID 29980405 DOI: 10.1016/J.Jbior.2018.06.002 |
0.426 |
|
| 2018 |
Drulis-Fajdasz D, Rakus D, Wiśniewski JR, McCubrey JA, Gizak A. Systematic analysis of GSK-3 signaling pathways in aging of cerebral tissue. Advances in Biological Regulation. 69: 35-42. PMID 29958836 DOI: 10.1016/J.Jbior.2018.06.001 |
0.387 |
|
| 2018 |
Evangelisti C, Chiarini F, McCubrey JA, Martelli AM. Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. International Journal of Molecular Sciences. 19. PMID 29949919 DOI: 10.3390/Ijms19071878 |
0.435 |
|
| 2018 |
Chappell WH, Candido S, Abrams SL, Russo S, Ove R, Martelli AM, Cocco L, Ramazzotti G, Cervello M, Montalto G, Steelman LS, Leng X, Arlinghaus RB, Libra M, McCubrey JA. Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell lines. Advances in Biological Regulation. PMID 29861174 DOI: 10.1016/J.Jbior.2018.05.002 |
0.362 |
|
| 2018 |
Simioni C, Martelli AM, Zauli G, Vitale M, McCubrey JA, Capitani S, Neri LM. Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update. Journal of Cellular Physiology. PMID 29667769 DOI: 10.1002/Jcp.26539 |
0.449 |
|
| 2018 |
Leonardi GC, Falzone L, Salemi R, Zanghì A, Spandidos DA, Mccubrey JA, Candido S, Libra M. Cutaneous melanoma: From pathogenesis to therapy (Review). International Journal of Oncology. 52: 1071-1080. PMID 29532857 DOI: 10.3892/Ijo.2018.4287 |
0.407 |
|
| 2018 |
Martelli AM, Buontempo F, McCubrey JA. Drug discovery targeting the mTOR pathway. Clinical Science (London, England : 1979). 132: 543-568. PMID 29523752 DOI: 10.1042/Cs20171158 |
0.442 |
|
| 2018 |
Mammana S, Bramanti P, Mazzon E, Cavalli E, Basile MS, Fagone P, Petralia MC, McCubrey JA, Nicoletti F, Mangano K. Preclinical evaluation of the PI3K/Akt/mTOR pathway in animal models of multiple sclerosis. Oncotarget. 9: 8263-8277. PMID 29492193 DOI: 10.18632/Oncotarget.23862 |
0.378 |
|
| 2018 |
Candido S, Abrams SL, Steelman L, Lertpiriyapong K, Martelli AM, Cocco L, Ratti S, Follo MY, Murata RM, Rosalen PL, Lombardi P, Montalto G, Cervello M, Gizak A, Rakus D, ... ... McCubrey JA, et al. Metformin influences drug sensitivity in pancreatic cancer cells. Advances in Biological Regulation. PMID 29482945 DOI: 10.1016/J.Jbior.2018.02.002 |
0.375 |
|
| 2017 |
Wiśniewski J, Piróg M, Hołubowicz R, Dobryszycki P, McCubrey JA, Rakus D, Gizak A. Dimeric and tetrameric forms of muscle fructose-1,6-bisphosphatase play different roles in the cell. Oncotarget. 8: 115420-115433. PMID 29383170 DOI: 10.18632/Oncotarget.23271 |
0.407 |
|
| 2017 |
Steelman LS, Abrams SL, Ruvolo P, Ruvolo V, Cocco L, Ratti S, Martelli AM, Neri LM, Candido S, Libra M, McCubrey JA. Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression. Oncotarget. 8: 113013-113033. PMID 29348885 DOI: 10.18632/Oncotarget.22956 |
0.417 |
|
| 2017 |
Zawiślak A, Jakimowicz P, McCubrey JA, Rakus D. Neuron-derived transthyretin modulates astrocytic glycolysis in hormone-independent manner. Oncotarget. 8: 106625-106638. PMID 29290976 DOI: 10.18632/Oncotarget.22542 |
0.325 |
|
| 2017 |
Opyrchal M, Gil M, Salisbury JL, Goetz MP, Suman V, Degnim A, McCubrey J, Haddad T, Iankov I, Kurokawa CB, Shumacher N, Ingle JN, Galanis E, D'Assoro AB. Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells. Oncotarget. 8: 91803-91816. PMID 29207686 DOI: 10.18632/Oncotarget.20610 |
0.407 |
|
| 2017 |
Ratti S, Ramazzotti G, Faenza I, Fiume R, Mongiorgi S, Billi AM, McCubrey JA, Suh PG, Manzoli L, Cocco L, Follo MY. Nuclear inositide signaling and cell cycle. Advances in Biological Regulation. PMID 29102395 DOI: 10.1016/J.Jbior.2017.10.008 |
0.51 |
|
| 2017 |
Abrams SL, Ruvolo PP, Ruvolo VR, Ligresti G, Martelli AM, Cocco L, Ratti S, Tafuri A, Steelman LS, Candido S, Libra M, McCubrey JA. Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. Oncotarget. 8: 76525-76557. PMID 29100331 DOI: 10.18632/Oncotarget.20408 |
0.517 |
|
| 2017 |
McCubrey JA, Abrams SL, Lertpiriyapong K, Cocco L, Ratti S, Martelli AM, Candido S, Libra M, Murata RM, Rosalen PL, Lombardi P, Montalto G, Cervello M, Gizak A, Rakus D, et al. Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells-Power of nutraceuticals. Advances in Biological Regulation. PMID 28988970 DOI: 10.1016/J.Jbior.2017.09.012 |
0.38 |
|
| 2017 |
Poli A, Ratti S, Finelli C, Mongiorgi S, Clissa C, Lonetti A, Cappellini A, Catozzi A, Barraco M, Suh PG, Manzoli L, McCubrey JA, Cocco L, Follo MY. Nuclear translocation of PKC-α is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs). Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 28970249 DOI: 10.1096/Fj.201700690R |
0.389 |
|
| 2017 |
Buontempo F, McCubrey JA, Orsini E, Ruzzene M, Cappellini A, Lonetti A, Evangelisti C, Chiarini F, Evangelisti C, Barata JT, Martelli AM. Therapeutic targeting of CK2 in acute and chronic leukemias. Leukemia. PMID 28951560 DOI: 10.1038/leu.2017.301 |
0.385 |
|
| 2017 |
McCubrey JA, Lertpiriyapong K, Steelman LS, Abrams SL, Cocco L, Ratti S, Martelli AM, Candido S, Libra M, Montalto G, Cervello M, Gizak A, Rakus D. Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases. Advances in Biological Regulation. PMID 28579298 DOI: 10.1016/J.Jbior.2017.05.005 |
0.407 |
|
| 2017 |
Ultimo S, Simioni C, Martelli AM, Zauli G, Evangelisti C, Celeghini C, McCubrey JA, Marisi G, Ulivi P, Capitani S, Neri LM. PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. Oncotarget. PMID 28390196 DOI: 10.18632/Oncotarget.15542 |
0.475 |
|
| 2017 |
Milella M, Falcone I, Conciatori F, Matteoni S, Sacconi A, De Luca T, Bazzichetto C, Corbo V, Simbolo M, Sperduti I, Benfante A, Del Curatolo A, Cesta Incani U, Malusa F, Eramo A, ... ... McCubrey JA, et al. PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer. Scientific Reports. 7: 43013. PMID 28220839 DOI: 10.1038/Srep43013 |
0.473 |
|
| 2017 |
Ratti S, Mongiorgi S, Ramazzotti G, Follo MY, Mariani GA, Suh PG, McCubrey JA, Cocco L, Manzoli L. Nuclear Inositide Signaling via Phospholipase C. Journal of Cellular Biochemistry. PMID 28106288 DOI: 10.1002/Jcb.25894 |
0.413 |
|
| 2017 |
Leontovich A, Salisbury J, Haddox CL, Mills L, Haddad T, McCubrey J, Goetz M, Ingle J, Galanis E, D'Assoro AB. Abstract 4851: NOTCH signaling promotes metastatic seeding and growth of human breast cancer cells Cancer Research. 77: 4851-4851. DOI: 10.1158/1538-7445.Am2017-4851 |
0.396 |
|
| 2016 |
McCubrey JA, Fitzgerald TL, Yang LV, Lertpiriyapong K, Steelman LS, Abrams SL, Montalto G, Cervello M, Neri LM, Cocco L, Martelli AM, Laidler P, DuliÅ Ska-Litewka J, Rakus D, Gizak A, et al. Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells. Oncotarget. PMID 27999207 DOI: 10.18632/Oncotarget.13991 |
0.47 |
|
| 2016 |
Simioni C, Ultimo S, Martelli AM, Zauli G, Milani D, McCubrey JA, Capitani S, Neri LM. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia. Oncotarget. PMID 27821800 DOI: 10.18632/Oncotarget.13035 |
0.53 |
|
| 2016 |
Ramazzotti G, Faenza I, Fiume R, Billi AM, Manzoli L, Mongiorgi S, Ratti S, McCubrey JA, Suh PG, Cocco L, Follo MY. PLC-β1 and cell differentiation: An insight into myogenesis and osteogenesis. Advances in Biological Regulation. PMID 27776973 DOI: 10.1016/J.Jbior.2016.10.005 |
0.307 |
|
| 2016 |
McCubrey JA, Lertpiriyapong K, Fitzgerald TL, Martelli AM, Cocco L, Rakus D, Gizak A, Libra M, Cervello M, Montalto G, Yang LV, Abrams SL, Steelman LS. Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis. Advances in Biological Regulation. PMID 27776972 DOI: 10.1016/J.Jbior.2016.10.001 |
0.41 |
|
| 2016 |
McCubrey JA, Rakus D, Gizak A, Steelman LS, Abrams SL, Lertpiriyapong K, Fitzgerald TL, Yang LV, Montalto G, Cervello M, Libra M, Nicoletti F, Scalisi A, Torino F, Fenga C, et al. Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer. Biochimica Et Biophysica Acta. PMID 27612668 DOI: 10.1016/J.Bbamcr.2016.09.004 |
0.457 |
|
| 2016 |
Alameen AA, Simioni C, Martelli AM, Zauli G, Ultimo S, McCubrey JA, Gonelli A, Marisi G, Ulivi P, Capitani S, Neri LM. Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia. Oncotarget. PMID 27494886 DOI: 10.18632/Oncotarget.10984 |
0.516 |
|
| 2016 |
Emma MR, Iovanna JL, Bachvarov D, Puleio R, Loria GR, Augello G, Candido S, Libra M, Gulino A, Cancila V, McCubrey JA, Montalto G, Cervello M. NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance. Cell Death & Disease. 7: e2269. PMID 27336713 DOI: 10.1038/Cddis.2016.175 |
0.394 |
|
| 2016 |
Steelman LS, Martelli AM, Cocco L, Libra M, Nicoletti F, Abrams SL, McCubrey JA. The Therapeutic Potential of mTOR Inhibitors in Breast Cancer. British Journal of Clinical Pharmacology. PMID 27059645 DOI: 10.1111/Bcp.12958 |
0.301 |
|
| 2016 |
Pappalardo F, Russo G, Candido S, Pennisi M, Cavalieri S, Motta S, McCubrey JA, Nicoletti F, Libra M. Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer. Plos One. 11: e0152104. PMID 27015094 DOI: 10.1371/Journal.Pone.0152104 |
0.513 |
|
| 2016 |
Steelman LS, Fitzgerald T, Lertpiriyapong K, Cocco L, Follo MY, Martelli AM, Neri LM, Marmiroli S, Libra M, Candido S, Nicoletti F, Scalisi A, Fenga C, Drobot L, Rakus D, ... ... McCubrey JA, et al. Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy. Current Pharmaceutical Design. PMID 26947958 DOI: 10.2174/1381612822666160304151011 |
0.306 |
|
| 2016 |
Mongiorgi S, Follo MY, Yang YR, Manzoli L, McCubrey JA, Billi AM, Suh PG, Cocco L. Selective Activation of Nuclear PI-PLCbeta1 during Normal and Therapy-Related Differentiation. Current Pharmaceutical Design. PMID 26916022 DOI: 10.2174/1381612822666160226132338 |
0.427 |
|
| 2016 |
Augello G, Puleio R, Emma MR, Cusimano A, Loria GR, McCubrey JA, Montalto G, Cervello M. A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells. Cell Cycle (Georgetown, Tex.). 15: 573-83. PMID 26794644 DOI: 10.1080/15384101.2016.1138183 |
0.378 |
|
| 2016 |
Chiarini F, Lonetti A, Evangelisti C, Buontempo F, Orsini E, Evangelisti C, Cappellini A, Neri LM, McCubrey JA, Martelli AM. Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting. Biochimica Et Biophysica Acta. 1863: 449-63. PMID 26334291 DOI: 10.1016/j.bbamcr.2015.08.015 |
0.353 |
|
| 2015 |
Poli A, Billi AM, Mongiorgi S, Ratti S, McCubrey JA, Suh PG, Cocco L, Ramazzotti G. Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phosphate Kinases and Phospholipases C. Journal of Cellular Physiology. PMID 26626942 DOI: 10.1002/jcp.25273 |
0.372 |
|
| 2015 |
Mongiorgi S, Finelli C, Yang YR, Clissa C, McCubrey JA, Billi AM, Manzoli L, Suh PG, Cocco L, Follo MY. Inositide-dependent Signaling Pathways as New Therapeutic Targets in Myelodysplastic Syndromes. Expert Opinion On Therapeutic Targets. PMID 26610046 DOI: 10.1517/14728222.2016.1125885 |
0.302 |
|
| 2015 |
Buontempo F, Orsini E, Lonetti A, Cappellini A, Chiarini F, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, Bertacchini J, Neri LM, McCubrey JA, Martelli AM. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB. Oncotarget. PMID 26593250 DOI: 10.18632/oncotarget.6361 |
0.367 |
|
| 2015 |
Iacovelli S, Ricciardi MR, Allegretti M, Mirabilii S, Licchetta R, Bergamo P, Rinaldo C, Zeuner A, Foà R, Milella M, McCubrey JA, Martelli AM, Tafuri A. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. Oncotarget. 6: 32089-103. PMID 26392332 DOI: 10.18632/oncotarget.5156 |
0.343 |
|
| 2015 |
Fitzgerald TL, Lertpiriyapong K, Cocco L, Martelli AM, Libra M, Candido S, Montalto G, Cervello M, Steelman L, Abrams SL, McCubrey JA. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. Advances in Biological Regulation. 59: 65-81. PMID 26257206 DOI: 10.1016/j.jbior.2015.06.003 |
0.339 |
|
| 2015 |
Simioni C, Cani A, Martelli AM, Zauli G, Alameen AA, Ultimo S, Tabellini G, McCubrey JA, Capitani S, Neri LM. The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells. Oncotarget. 6: 17147-60. PMID 26003166 DOI: 10.18632/oncotarget.3940 |
0.367 |
|
| 2015 |
Lonetti A, Cappellini A, Spartà AM, Chiarini F, Buontempo F, Evangelisti C, Evangelisti C, Orsini E, McCubrey JA, Martelli AM. PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. Oncotarget. 6: 10399-414. PMID 25871383 DOI: 10.18632/oncotarget.3295 |
0.338 |
|
| 2015 |
Cani A, Simioni C, Martelli AM, Zauli G, Tabellini G, Ultimo S, McCubrey JA, Capitani S, Neri LM. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. Oncotarget. 6: 6597-610. PMID 25788264 DOI: 10.18632/oncotarget.3260 |
0.376 |
|
| 2015 |
Cusimano A, Puleio R, D'Alessandro N, Loria GR, McCubrey JA, Montalto G, Cervello M. Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells. Oncotarget. 6: 1707-22. PMID 25596737 DOI: 10.18632/oncotarget.2738 |
0.355 |
|
| 2015 |
Chiarini F, Evangelisti C, McCubrey JA, Martelli AM. Current treatment strategies for inhibiting mTOR in cancer. Trends in Pharmacological Sciences. 36: 124-35. PMID 25497227 DOI: 10.1016/j.tips.2014.11.004 |
0.355 |
|
| 2015 |
Follo MY, Manzoli L, Poli A, McCubrey JA, Cocco L. PLC and PI3K/Akt/mTOR signalling in disease and cancer. Advances in Biological Regulation. 57: 10-6. PMID 25482988 DOI: 10.1016/j.jbior.2014.10.004 |
0.427 |
|
| 2015 |
McCubrey JA, Abrams SL, Fitzgerald TL, Cocco L, Martelli AM, Montalto G, Cervello M, Scalisi A, Candido S, Libra M, Steelman LS. Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. Advances in Biological Regulation. 57: 75-101. PMID 25453219 DOI: 10.1016/j.jbior.2014.09.016 |
0.417 |
|
| 2015 |
Simioni C, Cani A, Martelli AM, Zauli G, Tabellini G, McCubrey J, Capitani S, Neri LM. Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. Oncotarget. 5: 10034-47. PMID 25296981 DOI: 10.18632/Oncotarget.2490 |
0.522 |
|
| 2015 |
Yeung F, Ramsey CS, Popko-Scibor AE, Allison DF, Gray LG, Shin M, Kumar M, Li D, McCubrey JA, Mayo MW. Regulation of the mitogen-activated protein kinase kinase (MEK)-1 by NAD(+)-dependent deacetylases. Oncogene. 34: 798-804. PMID 24681949 DOI: 10.1038/Onc.2014.39 |
0.458 |
|
| 2015 |
Candido S, Malaponte G, Salemi R, Pezzino FM, Scalisi A, McCubrey JA, Libra M. Abstract 4304: MMP-9 as a marker of response to treatment with B-Raf inhibitors in cutaneous melanoma Cancer Research. 75: 4304-4304. DOI: 10.1158/1538-7445.Am2015-4304 |
0.346 |
|
| 2015 |
McCubrey JA, Steelman LS, Bäsecke J, Martelli AM. Raf/mek/erk signaling Targeted Therapy of Acute Myeloid Leukemi. 275-305. DOI: 10.1007/978-1-4939-1393-0_14 |
0.415 |
|
| 2014 |
Poli A, Ramazzotti G, Matteucci A, Manzoli L, Lonetti A, Suh PG, McCubrey JA, Cocco L. A novel DAG-dependent mechanism links PKCɑ and Cyclin B1 regulating cell cycle progression. Oncotarget. 5: 11526-40. PMID 25362646 DOI: 10.18632/Oncotarget.2578 |
0.418 |
|
| 2014 |
Evangelisti C, Evangelisti C, Teti G, Chiarini F, Falconi M, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Beak DJ, Bittman R, Pyne S, Pyne NJ, Martelli AM. Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. Oncotarget. 5: 7886-901. PMID 25226616 DOI: 10.18632/Oncotarget.2318 |
0.544 |
|
| 2014 |
McCubrey JA, Cocco L. Foreword: "Targeting signaling pathways in stem cells". Advances in Biological Regulation. 56: 1-5. PMID 25088602 DOI: 10.1016/J.Jbior.2014.07.001 |
0.429 |
|
| 2014 |
Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra M, Candido S, Nicoletti F, Polesel J, Maestro R, D'Assoro A, Drobot L, Rakus D, Gizak A, Laidler P, Dulińska-Litewka J, ... ... McCubrey JA, et al. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget. 5: 4603-50. PMID 25051360 DOI: 10.18632/Oncotarget.2209 |
0.335 |
|
| 2014 |
Opyrchal M, Salisbury JL, Iankov I, Goetz MP, McCubrey J, Gambino MW, Malatino L, Puccia G, Ingle JN, Galanis E, D'Assoro AB. Inhibition of Cdk2 kinase activity selectively targets the CD44 +/CD24-/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells International Journal of Oncology. 45: 1193-1199. PMID 24970653 DOI: 10.3892/Ijo.2014.2523 |
0.397 |
|
| 2014 |
Evangelisti C, Evangelisti C, Chiarini F, Lonetti A, Buontempo F, Bressanin D, Cappellini A, Orsini E, McCubrey JA, Martelli AM. Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review). International Journal of Oncology. 45: 909-18. PMID 24968804 DOI: 10.3892/Ijo.2014.2525 |
0.369 |
|
| 2014 |
Bavelloni A, Poli A, Fiume R, Blalock W, Matteucci A, Ramazzotti G, McCubrey JA, Cocco L, Faenza I. PLC-beta 1 regulates the expression of miR-210 during mithramycin-mediated erythroid differentiation in K562 cells. Oncotarget. 5: 4222-31. PMID 24962066 DOI: 10.18632/Oncotarget.1972 |
0.639 |
|
| 2014 |
Bertrand FE, McCubrey JA, Angus CW, Nutter JM, Sigounas G. NOTCH and PTEN in prostate cancer. Advances in Biological Regulation. 56: 51-65. PMID 24933481 DOI: 10.1016/J.Jbior.2014.05.002 |
0.402 |
|
| 2014 |
McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Sokolosky M, Abrams SL, Montalto G, D'Assoro AB, Libra M, Nicoletti F, Maestro R, Basecke J, Rakus D, Gizak A, Demidenko ZN, et al. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget. 5: 2881-911. PMID 24931005 DOI: 10.18632/Oncotarget.2037 |
0.348 |
|
| 2014 |
Fitzgerald TL, McCubrey JA. Pancreatic cancer stem cells: association with cell surface markers, prognosis, resistance, metastasis and treatment. Advances in Biological Regulation. 56: 45-50. PMID 24925031 DOI: 10.1016/J.Jbior.2014.05.001 |
0.33 |
|
| 2014 |
McCubrey JA, Davis NM, Abrams SL, Montalto G, Cervello M, Libra M, Nicoletti F, D'Assoro AB, Cocco L, Martelli AM, Steelman LS. Targeting breast cancer initiating cells: advances in breast cancer research and therapy. Advances in Biological Regulation. 56: 81-107. PMID 24913694 DOI: 10.1016/J.Jbior.2014.05.003 |
0.314 |
|
| 2014 |
Russo A, Ficili B, Candido S, Pezzino FM, Guarneri C, Biondi A, Travali S, McCubrey JA, Spandidos DA, Libra M. Emerging targeted therapies for melanoma treatment (review). International Journal of Oncology. 45: 516-24. PMID 24899250 DOI: 10.3892/Ijo.2014.2481 |
0.456 |
|
| 2014 |
Spartà AM, Bressanin D, Chiarini F, Lonetti A, Cappellini A, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Martelli AM. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia. Cell Cycle (Georgetown, Tex.). 13: 2237-47. PMID 24874015 DOI: 10.4161/cc.29267 |
0.413 |
|
| 2014 |
Opyrchal M, Salisbury JL, Zhang S, McCubrey J, Hawse J, Goetz MP, Lomberk GA, Haddad T, Degnim A, Lange C, Ingle JN, Galanis E, D'Assoro AB. Aurora-A mitotic kinase induces endocrine resistance through down-regulation of ERα expression in initially ERα+ breast cancer cells. Plos One. 9: e96995. PMID 24816249 DOI: 10.1371/Journal.Pone.0096995 |
0.456 |
|
| 2014 |
Candido S, Maestro R, Polesel J, Catania A, Maira F, Signorelli SS, McCubrey JA, Libra M. Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer Oncotarget. 5: 1576-1594. PMID 24742531 DOI: 10.18632/Oncotarget.1738 |
0.312 |
|
| 2014 |
Lonetti A, Antunes IL, Chiarini F, Orsini E, Buontempo F, Ricci F, Tazzari PL, Pagliaro P, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Barata JT, Martelli AM. Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia. Leukemia. 28: 1196-206. PMID 24310736 DOI: 10.1038/leu.2013.369 |
0.342 |
|
| 2014 |
Follo MY, Faenza I, Piazzi M, Blalock WL, Manzoli L, McCubrey JA, Cocco L. Nuclear PI-PLCβ1: an appraisal on targets and pathology. Advances in Biological Regulation. 54: 2-11. PMID 24296032 DOI: 10.1016/J.Jbior.2013.11.003 |
0.694 |
|
| 2014 |
Buontempo F, Orsini E, Martins LR, Antunes I, Lonetti A, Chiarini F, Tabellini G, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Cappellini A, et al. Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling. Leukemia. 28: 543-53. PMID 24253024 DOI: 10.1038/leu.2013.349 |
0.394 |
|
| 2014 |
Ciuffreda L, Incani UC, Steelman LS, Abrams SL, Falcone I, Curatolo AD, Chappell WH, Franklin RA, Vari S, Cognetti F, McCubrey JA, Milella M. Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLC. Current Pharmaceutical Design. 20: 3944-57. PMID 24138714 DOI: 10.2174/13816128113196660763 |
0.505 |
|
| 2014 |
McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Abrams SL, Montalto G, D'Assoro AB, Libra M, Nicoletti F, Maestro R, Basecke J, Cocco L, Cervello M, Martelli AM. Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia. 28: 15-33. PMID 23778311 DOI: 10.1038/Leu.2013.184 |
0.396 |
|
| 2014 |
D'Assoro AB, Liu T, Quatraro C, Amato A, Opyrchal M, Leontovich A, Ikeda Y, Ohmine S, Lingle W, Suman V, Ecsedy J, Iankov I, Di Leonardo A, Ayers-Inglers J, Degnim A, ... ... McCubrey J, et al. The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells. Oncogene. 33: 599-610. PMID 23334326 DOI: 10.1038/Onc.2012.628 |
0.493 |
|
| 2014 |
Opyrchal M, Salisbury JL, Zhang S, McCubrey J, Hawse J, Goetz MP, Haddad TC, Degnim AC, Lange CA, Ingle JN, Galanis E, D'Assoro A. Aurora-A mitotic kinase and induction of endocrine resistance through downregulation of erα expression in initially erα+ breast cancer cells. Journal of Clinical Oncology. 32: 2568-2568. DOI: 10.1200/Jco.2014.32.15_Suppl.2568 |
0.344 |
|
| 2013 |
Simioni C, Martelli AM, Cani A, Cetin-Atalay R, McCubrey JA, Capitani S, Neri LM. The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy. Oncotarget. 4: 1496-506. PMID 24036604 DOI: 10.18632/Oncotarget.1236 |
0.427 |
|
| 2013 |
Neri LM, Cani A, Martelli AM, Simioni C, Junghanss C, Tabellini G, Ricci F, Tazzari PL, Pagliaro P, McCubrey JA, Capitani S. Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential. Leukemia. 28: 739-48. PMID 23892718 DOI: 10.1038/leu.2013.226 |
0.397 |
|
| 2013 |
Cervello M, Bachvarov D, Lampiasi N, Cusimano A, Azzolina A, McCubrey JA, Montalto G. Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells. Plos One. 8: e65569. PMID 23776502 DOI: 10.1371/journal.pone.0065569 |
0.348 |
|
| 2013 |
Evangelisti C, Evangelisti C, Bressanin D, Buontempo F, Chiarini F, Lonetti A, Soncin M, Spartà A, McCubrey JA, Martelli AM. Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. Expert Opinion On Therapeutic Targets. 17: 921-36. PMID 23755894 DOI: 10.1517/14728222.2013.808333 |
0.504 |
|
| 2013 |
Poli A, Faenza I, Chiarini F, Matteucci A, McCubrey JA, Cocco L. K562 cell proliferation is modulated by PLCβ1 through a PKCα-mediated pathway. Cell Cycle (Georgetown, Tex.). 12: 1713-21. PMID 23656785 DOI: 10.4161/Cc.24806 |
0.476 |
|
| 2013 |
Leontovich AA, Salisbury JL, Veroux M, Tallarita T, Billadeau D, McCubrey J, Ingle J, Galanis E, D'Assoro AB. Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast cancer cells Oncology Reports. 29: 1785-1788. PMID 23446853 DOI: 10.3892/Or.2013.2313 |
0.422 |
|
| 2013 |
Follo MY, Marmiroli S, Faenza I, Fiume R, Ramazzotti G, Martelli AM, Gobbi P, McCubrey JA, Finelli C, Manzoli FA, Cocco L. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS. Advances in Biological Regulation. 53: 2-7. PMID 23058275 DOI: 10.1016/J.Jbior.2012.09.009 |
0.417 |
|
| 2013 |
Fagone P, Donia M, Mangano K, Quattrocchi C, Mammana S, Coco M, Libra M, McCubrey JA, Nicoletti F. Comparative study of rapamycin and temsirolimus demonstrates superimposable anti-tumour potency on prostate cancer cells. Basic & Clinical Pharmacology & Toxicology. 112: 63-9. PMID 22762560 DOI: 10.1111/J.1742-7843.2012.00923.X |
0.448 |
|
| 2013 |
Mijatović S, Pešić M, Mojić M, Banković J, Miljković Đ, Fagone P, Mangano K, Nicoletti F, McCubrey J, Tanić N, Maksimović-Ivanić D. No-Modified Saquinavir is Equally Efficient Against Doxorubicin Sensitive and Resistant Non-Small Cell Lung Carcinoma Cells / MODIFIKOVANA KOVANA FORMA SAKVINAVIRA EFIKASNO SU PRIMI RA RAST ĆELIJA NESITNOĆELIJSKOG KARCINOMA PLUĆA RAZLIČITE OSETUIVOSTI NA DOKSORUBICIN Journal of Medical Biochemistry. 32: 406-416. DOI: 10.2478/Jomb-2013-0050 |
0.416 |
|
| 2012 |
Berman AE, Leontieva OV, Natarajan V, McCubrey JA, Demidenko ZN, Nikiforov MA. Recent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes. Oncotarget. 3: 1522-32. PMID 23455653 DOI: 10.18632/Oncotarget.889 |
0.382 |
|
| 2012 |
McCubrey JA, Steelman LS, Chappell WH, Sun L, Davis NM, Abrams SL, Franklin RA, Cocco L, Evangelisti C, Chiarini F, Martelli AM, Libra M, Candido S, Ligresti G, Malaponte G, et al. Advances in targeting signal transduction pathways. Oncotarget. 3: 1505-21. PMID 23455493 DOI: 10.18632/Oncotarget.802 |
0.398 |
|
| 2012 |
Chiarini F, Lonetti A, Teti G, Orsini E, Bressanin D, Cappellini A, Ricci F, Tazzari PL, Ognibene A, Falconi M, Pagliaro P, Iacobucci I, Martinelli G, Amadori S, McCubrey JA, et al. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. Oncotarget. 3: 1615-28. PMID 23271044 DOI: 10.18632/Oncotarget.762 |
0.494 |
|
| 2012 |
Chappell WH, Abrams SL, Franklin RA, LaHair MM, Montalto G, Cervello M, Martelli AM, Nicoletti F, Candido S, Libra M, Polesel J, Talamini R, Milella M, Tafuri A, Steelman LS, ... McCubrey JA, et al. Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. Cell Cycle (Georgetown, Tex.). 11: 4447-61. PMID 23159854 DOI: 10.4161/Cc.22786 |
0.48 |
|
| 2012 |
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, Bäsecke J, Mijatovic S, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget. 3: 1068-111. PMID 23085539 DOI: 10.18632/Oncotarget.659 |
0.415 |
|
| 2012 |
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget. 3: 954-87. PMID 23006971 DOI: 10.18632/Oncotarget.652 |
0.386 |
|
| 2012 |
Bressanin D, Evangelisti C, Ricci F, Tabellini G, Chiarini F, Tazzari PL, Melchionda F, Buontempo F, Pagliaro P, Pession A, McCubrey JA, Martelli AM. Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels. Oncotarget. 3: 811-23. PMID 22885370 DOI: 10.18632/oncotarget.579 |
0.325 |
|
| 2012 |
Cervello M, Bachvarov D, Lampiasi N, Cusimano A, Azzolina A, McCubrey JA, Montalto G. Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle (Georgetown, Tex.). 11: 2843-55. PMID 22801548 DOI: 10.4161/Cc.21193 |
0.434 |
|
| 2012 |
Mojic M, Mijatovic S, Maksimovic-Ivanic D, Miljkovic D, Stosic-Grujicic S, Stankovic M, Mangano K, Travali S, Donia M, Fagone P, Zocca MB, Al-Abed Y, McCubrey JA, Nicoletti F. Therapeutic potential of nitric oxide-modified drugs in colon cancer cells. Molecular Pharmacology. 82: 700-10. PMID 22798453 DOI: 10.1124/Mol.112.077842 |
0.444 |
|
| 2012 |
Buontempo F, Chiarini F, Bressanin D, Tabellini G, Melchionda F, Pession A, Fini M, Neri LM, McCubrey JA, Martelli AM. Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a. Cell Cycle (Georgetown, Tex.). 11: 2467-75. PMID 22713244 DOI: 10.4161/Cc.20859 |
0.51 |
|
| 2012 |
Martelli AM, Chiarini F, Evangelisti C, Ognibene A, Bressanin D, Billi AM, Manzoli L, Cappellini A, McCubrey JA. Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. Expert Opinion On Therapeutic Targets. 16: 729-42. PMID 22686561 DOI: 10.1517/14728222.2012.694869 |
0.49 |
|
| 2012 |
Martelli AM, Chiarini F, Evangelisti C, Cappellini A, Buontempo F, Bressanin D, Fini M, McCubrey JA. Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget. 3: 371-94. PMID 22564882 DOI: 10.18632/Oncotarget.477 |
0.524 |
|
| 2012 |
Leontovich AA, Zhang S, Quatraro C, Iankov I, Veroux PF, Gambino MW, Degnim A, McCubrey J, Ingle J, Galanis E, D'Assoro AB. Raf-1 oncogenic signaling is linked to activation of mesenchymal to epithelial transition pathway in metastatic breast cancer cells. International Journal of Oncology. 40: 1858-64. PMID 22447278 DOI: 10.3892/Ijo.2012.1407 |
0.497 |
|
| 2012 |
Ricciardi MR, Scerpa MC, Bergamo P, Ciuffreda L, Petrucci MT, Chiaretti S, Tavolaro S, Mascolo MG, Abrams SL, Steelman LS, Tsao T, Marchetti A, Konopleva M, Del Bufalo D, Cognetti F, ... ... McCubrey JA, et al. Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies. Journal of Molecular Medicine (Berlin, Germany). 90: 1133-44. PMID 22399013 DOI: 10.1007/S00109-012-0886-Z |
0.516 |
|
| 2012 |
McCubrey JA, Steelman LS, Abrams SL, Misaghian N, Chappell WH, Basecke J, Nicoletti F, Libra M, Ligresti G, Stivala F, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, et al. Targeting the cancer initiating cell: the ultimate target for cancer therapy. Current Pharmaceutical Design. 18: 1784-95. PMID 22394167 DOI: 10.2174/138161212799859701 |
0.421 |
|
| 2012 |
Mojic M, Mijatovic S, Maksimovic-Ivanic D, Dinic S, Grdovic N, Miljkovic D, Stosic-Grujicic S, Tumino S, Fagone P, Mangano K, Zocca MB, Al-Abed Y, McCubrey JA, Nicoletti F. Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL. Cell Cycle (Georgetown, Tex.). 11: 1174-82. PMID 22370480 DOI: 10.4161/Cc.11.6.19611 |
0.483 |
|
| 2012 |
Follo MY, Mongiorgi S, Finelli C, Piazzi M, Faenza I, Ramazzotti G, Santi P, McCubrey JA, Martelli AM, Cocco L. Nuclear PI-PLCβ1 and myelodysplastic syndromes: genetics and epigenetics. Current Pharmaceutical Design. 18: 1751-4. PMID 22352752 DOI: 10.2174/138161212799859710 |
0.441 |
|
| 2012 |
Lampiasi N, Azzolina A, Umezawa K, Montalto G, McCubrey JA, Cervello M. The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. Cancer Letters. 322: 35-44. PMID 22343223 DOI: 10.1016/J.Canlet.2012.02.008 |
0.485 |
|
| 2012 |
Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F, Passeri D, Falcone I, Sette G, Bergamo P, Anichini A, Sabapathy K, McCubrey JA, Ricciardi MR, Tafuri A, et al. The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. Journal of Molecular Medicine (Berlin, Germany). 90: 667-79. PMID 22215152 DOI: 10.1007/S00109-011-0844-1 |
0.533 |
|
| 2012 |
Hafsi S, Pezzino FM, Candido S, Ligresti G, Spandidos DA, Soua Z, McCubrey JA, Travali S, Libra M. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). International Journal of Oncology. 40: 639-44. PMID 22200790 DOI: 10.3892/Ijo.2011.1312 |
0.54 |
|
| 2012 |
Maira F, Catania A, Candido S, Russo AE, McCubrey JA, Libra M, Malaponte G, Fenga C. Molecular targeted therapy in melanoma: a way to reverse resistance to conventional drugs. Current Drug Delivery. 9: 17-29. PMID 22023213 DOI: 10.2174/156720112798376032 |
0.322 |
|
| 2012 |
Martelli AM, Tabellini G, Ricci F, Evangelisti C, Chiarini F, Bortul R, McCubrey JA, Manzoli FA. PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy. Advances in Biological Regulation. 52: 214-27. PMID 21983557 DOI: 10.1016/J.Advenzreg.2011.09.019 |
0.444 |
|
| 2012 |
Follo MY, Faenza I, Fiume R, Ramazzotti G, McCubrey JA, Martelli AM, Manzoli FA, Cocco L. Revisiting nuclear phospholipase C signalling in MDS. Advances in Biological Regulation. 52: 2-6. PMID 21982979 DOI: 10.1016/J.Advenzreg.2011.09.018 |
0.305 |
|
| 2012 |
McCubrey J, Steelman L, Wang X, Davidian E, Hoyle P, White C, Prevost K, Algate P, Robbins P, Mylott D, White M. Autocrine growth-factor secretion after transformation of human cytokine-dependent cells by viral and cellular oncogenes. International Journal of Oncology. 7: 573-86. PMID 21552876 DOI: 10.3892/ijo.7.3.573 |
0.337 |
|
| 2012 |
McCubrey J, Steelman L, Wang X, Algate P, Hoyle P, White C, Davidian E, Prevost K, Robbins P, Mylott D, White M. Differential-effects of viral and cellular oncogenes on the growth factor-dependency of hematopoietic-cells. International Journal of Oncology. 7: 295-310. PMID 21552839 DOI: 10.3892/ijo.7.2.295 |
0.351 |
|
| 2011 |
Grimaldi C, Chiarini F, Tabellini G, Ricci F, Tazzari PL, Battistelli M, Falcieri E, Bortul R, Melchionda F, Iacobucci I, Pagliaro P, Martinelli G, Pession A, Barata JT, McCubrey JA, et al. AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. Leukemia. 26: 91-100. PMID 21968881 DOI: 10.1038/leu.2011.269 |
0.357 |
|
| 2011 |
Martelli AM, Ognibene A, Buontempo F, Fini M, Bressanin D, Goto K, McCubrey JA, Cocco L, Evangelisti C. Nuclear phosphoinositides and their roles in cell biology and disease. Critical Reviews in Biochemistry and Molecular Biology. 46: 436-57. PMID 21913876 DOI: 10.3109/10409238.2011.609530 |
0.369 |
|
| 2011 |
Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Steelman LS, McCubrey JA. Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. Oncotarget. 2: 610-26. PMID 21881167 DOI: 10.18632/Oncotarget.315 |
0.451 |
|
| 2011 |
Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong EW, Martelli AM, Cocco L, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, McCubrey JA. Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle (Georgetown, Tex.). 10: 3003-15. PMID 21869603 DOI: 10.4161/Cc.10.17.17119 |
0.755 |
|
| 2011 |
Caputo E, Maiorana L, Vasta V, Pezzino FM, Sunkara S, Wynne K, Elia G, Marincola FM, McCubrey JA, Libra M, Travali S, Kane M. Characterization of human melanoma cell lines and melanocytes by proteome analysis. Cell Cycle (Georgetown, Tex.). 10: 2924-36. PMID 21857157 DOI: 10.4161/Cc.10.17.17068 |
0.335 |
|
| 2011 |
Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, Martelli AM, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, Steelman LS, McCubrey JA. Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget. 2: 538-50. PMID 21730367 DOI: 10.18632/Oncotarget.302 |
0.362 |
|
| 2011 |
Martelli AM, Evangelisti C, Follo MY, Ramazzotti G, Fini M, Giardino R, Manzoli L, McCubrey JA, Cocco L. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. Current Medicinal Chemistry. 18: 2715-26. PMID 21649579 DOI: 10.2174/092986711796011201 |
0.439 |
|
| 2011 |
Nicoletti F, Fagone P, Meroni P, McCubrey J, Bendtzen K. MTOR as a multifunctional therapeutic target in HIV infection Drug Discovery Today. 16: 715-721. PMID 21624501 DOI: 10.1016/J.Drudis.2011.05.008 |
0.322 |
|
| 2011 |
Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo P, Ruvolo V, Evangelisti C, Martelli AM, ... McCubrey JA, et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia. 25: 1080-94. PMID 21494257 DOI: 10.1038/Leu.2011.66 |
0.41 |
|
| 2011 |
Steelman LS, Martelli AM, Nicoletti F, McCubrey JA. Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity. Oncotarget. 2: 109-12. PMID 21487160 DOI: 10.18632/Oncotarget.247 |
0.307 |
|
| 2011 |
Martelli AM, Evangelisti C, Chappell W, Abrams SL, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo V, Ruvolo P, Kempf CR, Steelman LS, McCubrey JA. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia. 25: 1064-79. PMID 21436840 DOI: 10.1038/Leu.2011.46 |
0.439 |
|
| 2011 |
Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti F, Libra M, ... ... McCubrey JA, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging. 3: 192-222. PMID 21422497 |
0.425 |
|
| 2011 |
Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, ... ... McCubrey JA, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget. 2: 135-64. PMID 21411864 DOI: 10.18632/Oncotarget.240 |
0.429 |
|
| 2011 |
Cervello M, Bachvarov D, Cusimano A, Sardina F, Azzolina A, Lampiasi N, Giannitrapani L, McCubrey JA, Montalto G. COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells. Omics : a Journal of Integrative Biology. 15: 383-92. PMID 21410330 DOI: 10.1089/Omi.2010.0092 |
0.329 |
|
| 2011 |
Evangelisti C, Ricci F, Tazzari P, Tabellini G, Battistelli M, Falcieri E, Chiarini F, Bortul R, Melchionda F, Pagliaro P, Pession A, McCubrey JA, Martelli AM. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia. 25: 781-91. PMID 21331075 DOI: 10.1038/leu.2011.20 |
0.368 |
|
| 2011 |
McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, Bäsecke J, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Cocco L, et al. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. Journal of Cellular Physiology. 226: 2762-81. PMID 21302297 DOI: 10.1002/Jcp.22647 |
0.384 |
|
| 2011 |
Donia M, Maksimovic-Ivanic D, Mijatovic S, Mojic M, Miljkovic D, Timotijevic G, Fagone P, Caponnetto S, Al-Abed Y, McCubrey J, Stosic-Grujicic S, Nicoletti F. In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. Cell Cycle (Georgetown, Tex.). 10: 492-9. PMID 21270522 DOI: 10.4161/Cc.10.3.14727 |
0.455 |
|
| 2011 |
Gil D, Ciołczyk-Wierzbicka D, Dulińska-Litewka J, Zwawa K, McCubrey JA, Laidler P. The mechanism of contribution of integrin linked kinase (ILK) to epithelial-mesenchymal transition (EMT). Advances in Enzyme Regulation. 51: 195-207. PMID 21035499 DOI: 10.1016/J.Advenzreg.2010.09.005 |
0.384 |
|
| 2011 |
McCubrey JA, Chappell WH, Abrams SL, Franklin RA, Long JM, Sattler JA, Kempf CR, Laidler P, Steelman LS. Targeting the cancer initiating cell: the Achilles' heel of cancer. Advances in Enzyme Regulation. 51: 152-62. PMID 21035484 DOI: 10.1016/J.Advenzreg.2010.09.002 |
0.374 |
|
| 2011 |
Evangelisti C, Ricci F, Tazzari P, Chiarini F, Battistelli M, Falcieri E, Ognibene A, Pagliaro P, Cocco L, McCubrey JA, Martelli AM. Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. Journal of Cellular Physiology. 226: 822-31. PMID 20857426 DOI: 10.1002/Jcp.22407 |
0.49 |
|
| 2011 |
Chiarini F, Grimaldi C, Ricci F, Tazzari P, Iacobucci I, Martinelli G, Pagliaro P, McCubrey J, Amadori S, Martelli AM. Temsirolimus, An Allosteric mTORC1 Inhibitor, Is Synergistic with Clofarabine in AML and AML Leukemia Initiating Cells Blood. 118: 2596-2596. DOI: 10.1182/Blood.V118.21.2596.2596 |
0.533 |
|
| 2010 |
Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, McCubrey JA. The emerging role of the phosphatidylinositol 3-kinase/ akt/mammalian target of rapamycin signaling network in cancer stem cell biology. Cancers. 2: 1576-96. PMID 24281174 DOI: 10.3390/Cancers2031576 |
0.5 |
|
| 2010 |
Chiarini F, Grimaldi C, Ricci F, Tazzari PL, Evangelisti C, Ognibene A, Battistelli M, Falcieri E, Melchionda F, Pession A, Pagliaro P, McCubrey JA, Martelli AM. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Research. 70: 8097-107. PMID 20876803 DOI: 10.1158/0008-5472.Can-10-1814 |
0.502 |
|
| 2010 |
Martelli AM, Evangelisti C, Chiarini F, McCubrey JA. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget. 1: 89-103. PMID 20671809 DOI: 10.18632/Oncotarget.114 |
0.533 |
|
| 2010 |
Abrams SL, Steelman LS, Shelton JG, Wong EW, Chappell WH, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M, Martelli AM, McCubrey JA. The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle (Georgetown, Tex.). 9: 1781-91. PMID 20436278 DOI: 10.4161/Cc.9.9.11483 |
0.744 |
|
| 2010 |
Abrams SL, Steelman LS, Shelton JG, Chappell W, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M, Martelli AM, McCubrey JA. Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. Cell Cycle (Georgetown, Tex.). 9: 1839-46. PMID 20436269 DOI: 10.4161/Cc.9.9.11544 |
0.788 |
|
| 2010 |
Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Cappellini A, Ognibene A, McCubrey JA. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochimica Et Biophysica Acta. 1803: 991-1002. PMID 20399811 DOI: 10.1016/J.Bbamcr.2010.04.005 |
0.517 |
|
| 2010 |
Steelman LS, Abrams SL, Shelton JG, Chappell WH, Bäsecke J, Stivala F, Donia M, Nicoletti F, Libra M, Martelli AM, McCubrey JA. Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. Cell Cycle (Georgetown, Tex.). 9: 1629-38. PMID 20372086 DOI: 10.4161/Cc.9.8.11487 |
0.787 |
|
| 2010 |
Cusimano A, Azzolina A, Iovanna JL, Bachvarov D, McCubrey JA, D'Alessandro N, Montalto G, Cervello M. Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle (Georgetown, Tex.). 9: 1399-410. PMID 20305374 |
0.364 |
|
| 2010 |
Martelli AM, Chiarini F, Evangelisti C, Grimaldi C, Ognibene A, Manzoli L, Billi AM, McCubrey JA. The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis. Histology and Histopathology. 25: 669-80. PMID 20238304 DOI: 10.14670/Hh-25.669 |
0.512 |
|
| 2010 |
Martelli AM, Papa V, Tazzari PL, Ricci F, Evangelisti C, Chiarini F, Grimaldi C, Cappellini A, Martinelli G, Ottaviani E, Pagliaro P, Horn S, Bäsecke J, Lindner LH, Eibl H, ... McCubrey JA, et al. Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. Leukemia. 24: 687-98. PMID 20200557 DOI: 10.1038/leu.2010.32 |
0.379 |
|
| 2010 |
McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, et al. Emerging MEK inhibitors. Expert Opinion On Emerging Drugs. 15: 203-23. PMID 20151845 DOI: 10.1517/14728210903282760 |
0.437 |
|
| 2010 |
Mijatovic S, Maksimovic-Ivanic D, Timotijevic G, Miljkovic D, Donia M, Libra M, Coco M, McCubrey J, Al-Abed Y, Korac A, Stosic-Grujicic S, Nicoletti F. Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO. Free Radical Biology & Medicine. 48: 1090-9. PMID 20114073 DOI: 10.1016/J.Freeradbiomed.2010.01.026 |
0.482 |
|
| 2010 |
Castellano G, Torrisi E, Ligresti G, Nicoletti F, Malaponte G, Traval S, McCubrey JA, Canevari S, Libra M. Yin Yang 1 overexpression in diffuse large B-cell lymphoma is associated with B-cell transformation and tumor progression. Cell Cycle (Georgetown, Tex.). 9: 557-63. PMID 20081364 DOI: 10.4161/Cc.9.3.10554 |
0.374 |
|
| 2010 |
Evangelisti C, Gaboardi GC, Billi AM, Ognibene A, Goto K, Tazzari PL, McCubrey JA, Martelli AM. Identification of a functional nuclear export sequence in diacylglycerol kinase-zeta. Cell Cycle (Georgetown, Tex.). 9: 384-8. PMID 20023381 DOI: 10.4161/Cc.9.2.10469 |
0.424 |
|
| 2010 |
McCubrey JA, Abrams SL, Stadelman K, Chappell WH, Lahair M, Ferland RA, Steelman LS. Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. Advances in Enzyme Regulation. 50: 285-307. PMID 19895837 DOI: 10.1016/J.Advenzreg.2009.10.016 |
0.437 |
|
| 2010 |
Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, McCubrey JA. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opinion On Investigational Drugs. 18: 1333-49. PMID 19678801 DOI: 10.1517/14728220903136775 |
0.503 |
|
| 2010 |
McCubrey JA, Abrams SL, Chappell WH, Steelman LS, Ligresti G, Vella N, Marconi A, Proietti L, Nicoletti F, Libra M, Stivala F. Rationale for targeting of YY1 in drug-resistant leukemias Forum On Immunopathological Diseases and Therapeutics. 1: 65-79. DOI: 10.1615/Forumimmundisther.V1.I1-2.50 |
0.412 |
|
| 2010 |
Evangelisti C, Chiarini F, Ricci F, Tazzari P, Pession A, McCubrey JA, Martelli AM. Targeted Inhibition of mTORC1 and mTORC2 by the Active-Site mTOR Inhibitors, PP-242 and OSI-027, Has Cytotoxic Effects In T-Cell Acute Lymphoblastic Leukemia Blood. 116: 3242-3242. DOI: 10.1182/Blood.V116.21.3242.3242 |
0.45 |
|
| 2010 |
Grimaldi C, Chiarini F, Ricci F, Tazzari P, Battistelli M, Falcieri E, Pession A, McCubrey J, Martelli AM. AMP-Dependent Kinase/mTOR Complex 1 Signaling In T-Cell Acute Lymphoblastic Leukemia: Therapeutical Implications Blood. 116: 3225-3225. DOI: 10.1182/Blood.V116.21.3225.3225 |
0.516 |
|
| 2009 |
McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, et al. Emerging Raf inhibitors. Expert Opinion On Emerging Drugs. 14: 633-48. PMID 19715444 DOI: 10.1517/14728210903232633 |
0.506 |
|
| 2009 |
Franklin RA, McCubrey JA. The involvement of CaM-KII in insulin induced cell proliferation. Cell Cycle (Georgetown, Tex.). 8: 1979. PMID 19550154 DOI: 10.4161/Cc.8.13.9105 |
0.356 |
|
| 2009 |
Sánchez C, Mendoza P, Contreras HR, Vergara J, McCubrey JA, Huidobro C, Castellón EA. Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. The Prostate. 69: 1448-59. PMID 19496068 DOI: 10.1002/Pros.20991 |
0.364 |
|
| 2009 |
Lampiasi N, Azzolina A, D'Alessandro N, Umezawa K, McCubrey JA, Montalto G, Cervello M. Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism. Molecular Pharmacology. 76: 290-300. PMID 19461054 DOI: 10.1124/Mol.109.055418 |
0.519 |
|
| 2009 |
Russo AE, Torrisi E, Bevelacqua Y, Perrotta R, Libra M, McCubrey JA, Spandidos DA, Stivala F, Malaponte G. Melanoma: molecular pathogenesis and emerging target therapies (Review). International Journal of Oncology. 34: 1481-9. PMID 19424565 DOI: 10.3892/Ijo_00000277 |
0.52 |
|
| 2009 |
Maksimovic-Ivanic D, Mijatovic S, Miljkovic D, Harhaji-Trajkovic L, Timotijevic G, Mojic M, Dabideen D, Cheng KF, McCubrey JA, Mangano K, Al-Abed Y, Libra M, Garotta G, Stosic-Grujicic S, Nicoletti F. The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt. Molecular Cancer Therapeutics. 8: 1169-78. PMID 19417156 DOI: 10.1158/1535-7163.Mct-08-0998 |
0.515 |
|
| 2009 |
Chiarini F, Falà F, Tazzari PL, Ricci F, Astolfi A, Pession A, Pagliaro P, McCubrey JA, Martelli AM. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Research. 69: 3520-8. PMID 19351820 DOI: 10.1158/0008-5472.Can-08-4884 |
0.53 |
|
| 2009 |
Castellano G, Torrisi E, Ligresti G, Malaponte G, Militello L, Russo AE, McCubrey JA, Canevari S, Libra M. The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle (Georgetown, Tex.). 8: 1367-72. PMID 19342874 DOI: 10.4161/Cc.8.9.8314 |
0.389 |
|
| 2009 |
Cappellini A, Chiarini F, Ognibene A, McCubrey JA, Martelli AM. The cyclin-dependent kinase inhibitor roscovitine and the nucleoside analog sangivamycin induce apoptosis in caspase-3 deficient breast cancer cells independent of caspase mediated P-glycoprotein cleavage: implications for therapy of drug resistant breast cancers. Cell Cycle (Georgetown, Tex.). 8: 1421-5. PMID 19342873 DOI: 10.4161/Cc.8.9.8323 |
0.405 |
|
| 2009 |
Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, Nicoletti F, Stivala F, McCubrey JA, Libra M. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle (Georgetown, Tex.). 8: 1352-8. PMID 19305151 DOI: 10.4161/Cc.8.9.8255 |
0.386 |
|
| 2009 |
Konkimalla VB, McCubrey JA, Efferth T. The role of downstream signaling pathways of the epidermal growth factor receptor for Artesunate's activity in cancer cells. Current Cancer Drug Targets. 9: 72-80. PMID 19200051 DOI: 10.2174/156800909787314020 |
0.459 |
|
| 2009 |
Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Bäsecke J, Libra M, Nicoletti F, Stivala F, Milella M, Tafuri A, Cervello M, Martelli AM, McCubrey JA. Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia. 23: 25-42. PMID 18800146 DOI: 10.1038/Leu.2008.246 |
0.324 |
|
| 2009 |
Steelman LS, McCubrey JA. Intriguing novel abilities of Nutlin-3A: Induction of cellular quiescence as opposed to cellular senescence—Implications for chemotherapy Cell Cycle. 8: 3631-3635. DOI: 10.4161/Cc.8.22.10165 |
0.301 |
|
| 2009 |
Ciuffreda L, McCubrey J, Milella M. Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments Current Signal Transduction Therapy. 4: 130-143. DOI: 10.2174/157436209788167466 |
0.453 |
|
| 2009 |
Ricciardi MR, Tsao T, Abrams SL, Bergamo P, Steelman LS, Decandia S, Felicioni L, Ciuffreda L, Di Sanza C, Marchetti A, Cognetti F, McCubrey J, Konopleva M, Andreeff M, Tafuri A, et al. Parallel Signaling through PI3K/AKT/mTOR Mediates Resistance to MEK Inhibition in Preclinical Models of Acute Myeloid Leukemia (AML): Synergistic Effects of Combined MEK and mTOR Inhibition. Blood. 114: 594-594. DOI: 10.1182/Blood.V114.22.594.594 |
0.481 |
|
| 2009 |
Konopleva M, Milella M, Watts JC, Ricciardi MR, Korchin B, Tsao T, Bergamo P, Mak DH, Decandia S, McCubrey J, Tafuri A, Andreeff M. Simultaneous Targeting of Bcl-2/Bcl-Xl and MEK/ERK Results in Highly Synergistic Induction of Apoptosis in Human AML, Both in Vitro and In Vivo. Blood. 114: 2757-2757. DOI: 10.1182/Blood.V114.22.2757.2757 |
0.45 |
|
| 2009 |
Chiarini F, Grimaldi C, Ricci F, Tazzari P, Evangelisti C, Pession A, Pagliaro P, McCubrey J, Martelli AM. Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin with NVP-BEZ235 as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia. Blood. 114: 2025-2025. DOI: 10.1182/Blood.V114.22.2025.2025 |
0.543 |
|
| 2009 |
Cervello M, Lampiasi N, Azzolina A, D'Alessandro N, Umezawa K, McCubrey J, Montalto G. 515 THE NOVEL NF-κB INHIBITOR DHMEQ SUPPRESSES THE GROWTH OF HUMAN HEPATIC CANCER CELLS THROUGH REDOX-DEPENDENT SIGNALING Journal of Hepatology. 50: S192. DOI: 10.1016/S0168-8278(09)60517-1 |
0.446 |
|
| 2008 |
Steelman LS, Navolanic PM, Franklin RA, Bonati A, Libra M, Stivala F, Martelli AM, McCubrey JA. Combining chemo-, hormonal and targeted therapies to treat breast cancer (Review). Molecular Medicine Reports. 1: 139-60. PMID 21479390 DOI: 10.3892/Mmr.1.2.139 |
0.784 |
|
| 2008 |
Tazzari PL, Tabellini G, Ricci F, Papa V, Bortul R, Chiarini F, Evangelisti C, Martinelli G, Bontadini A, Cocco L, McCubrey JA, Martelli AM. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Research. 68: 9394-403. PMID 19010914 DOI: 10.1158/0008-5472.CAN-08-2815 |
0.45 |
|
| 2008 |
Ruvolo VR, Kurinna SM, Karanjeet KB, Schuster TF, Martelli AM, McCubrey JA, Ruvolo PP. PKR regulates B56(alpha)-mediated BCL2 phosphatase activity in acute lymphoblastic leukemia-derived REH cells. The Journal of Biological Chemistry. 283: 35474-85. PMID 18957415 DOI: 10.1074/Jbc.M800951200 |
0.468 |
|
| 2008 |
Long JM, Bell CW, Fagg WS, Kushman ME, Becker KG, McCubrey JA, Farwell MA. Microarray and pathway analysis reveals decreased CDC25A and increased CDC42 associated with slow growth of BCL2 overexpressing immortalized breast cell line. Cell Cycle (Georgetown, Tex.). 7: 3062-73. PMID 18838868 DOI: 10.4161/Cc.7.19.6761 |
0.455 |
|
| 2008 |
Lehmann BD, Paine MS, Brooks AM, McCubrey JA, Renegar RH, Wang R, Terrian DM. Senescence-associated exosome release from human prostate cancer cells. Cancer Research. 68: 7864-71. PMID 18829542 DOI: 10.1158/0008-5472.Can-07-6538 |
0.332 |
|
| 2008 |
McCubrey JA, Bäsecke J, Cervello M, Martelli AM, Franklin RA. GSK-3beta is a critical mediator of tetrandrine induced cell cycle arrest and cytotoxicity. Cancer Biology & Therapy. 7: 1079. PMID 18698164 DOI: 10.4161/Cbt.7.7.6519 |
0.458 |
|
| 2008 |
Steelman LS, Stadelman KM, Chappell WH, Horn S, Bäsecke J, Cervello M, Nicoletti F, Libra M, Stivala F, Martelli AM, McCubrey JA. Akt as a therapeutic target in cancer. Expert Opinion On Therapeutic Targets. 12: 1139-65. PMID 18694380 DOI: 10.1517/14728222.12.9.1139 |
0.412 |
|
| 2008 |
Falà F, Blalock WL, Tazzari PL, Cappellini A, Chiarini F, Martinelli G, Tafuri A, McCubrey JA, Cocco L, Martelli AM. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia. Molecular Pharmacology. 74: 884-95. PMID 18577685 DOI: 10.1124/Mol.108.047639 |
0.674 |
|
| 2008 |
McCubrey JA, Sokolosky ML, Lehmann BD, Taylor JR, Navolanic PM, Chappell WH, Abrams SL, Stadelman KM, Wong EW, Misaghian N, Horn S, Bäsecke J, Libra M, Stivala F, Ligresti G, et al. Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. Advances in Enzyme Regulation. 48: 113-35. PMID 18423407 DOI: 10.1016/J.Advenzreg.2008.02.006 |
0.812 |
|
| 2008 |
Lehmann BD, Brooks AM, Paine MS, Chappell WH, McCubrey JA, Terrian DM. Distinct roles for p107 and p130 in Rb-independent cellular senescence. Cell Cycle (Georgetown, Tex.). 7: 1262-8. PMID 18418057 DOI: 10.4161/Cc.7.9.5945 |
0.417 |
|
| 2008 |
Chiarini F, Del Sole M, Mongiorgi S, Gaboardi GC, Cappellini A, Mantovani I, Follo MY, McCubrey JA, Martelli AM. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia. 22: 1106-16. PMID 18385752 DOI: 10.1038/leu.2008.79 |
0.381 |
|
| 2008 |
Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM, McCubrey JA. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia. 22: 686-707. PMID 18337767 DOI: 10.1038/Leu.2008.26 |
0.428 |
|
| 2008 |
McCubrey JA, Steelman LS, Abrams SL, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia. 22: 708-22. PMID 18337766 DOI: 10.1038/Leu.2008.27 |
0.428 |
|
| 2008 |
Steelman LS, Navolanic PM, Sokolosky ML, Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Wong EW, Stadelman KM, Terrian DM, Leslie NR, Martelli AM, Stivala F, Libra M, Franklin RA, ... McCubrey JA, et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene. 27: 4086-95. PMID 18332865 DOI: 10.1038/Onc.2008.49 |
0.75 |
|
| 2008 |
Horn S, Bergholz U, Jücker M, McCubrey JA, Trümper L, Stocking C, Bäsecke J. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells. Oncogene. 27: 4096-106. PMID 18317450 DOI: 10.1038/onc.2008.40 |
0.408 |
|
| 2008 |
Lee JT, Steelman LS, Chappell WH, McCubrey JA. Akt inactivates ERK causing decreased response to chemotherapeutic drugs in advanced CaP cells. Cell Cycle (Georgetown, Tex.). 7: 631-6. PMID 18256541 DOI: 10.4161/Cc.7.5.5416 |
0.521 |
|
| 2008 |
Ligresti G, Libra M, Militello L, Clementi S, Donia M, Imbesi R, Malaponte G, Cappellani A, McCubrey JA, Stivala F. Breast cancer: Molecular basis and therapeutic strategies (Review). Molecular Medicine Reports. 1: 451-458. DOI: 10.3892/Mmr.1.4.451 |
0.405 |
|
| 2008 |
Tazzari P, Papa V, Ricci F, Chiarini F, Evangelisti C, Martinelli G, Bontadini A, McCubrey J, Martelli AM. Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells-a Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling. Blood. 112: 957-957. DOI: 10.1182/Blood.V112.11.957.957 |
0.504 |
|
| 2008 |
Milella M, Ricciardi MR, Bergamo P, Scerpa MC, Gervasoni J, Petrucci MT, Chiaretti S, Tavolaro S, Ciuffreda L, Decandia S, Libotte F, Abrams SL, Steelman LS, Konopleva M, Cognetti F, ... ... McCubrey J, et al. Development of Mek inhibition (MEK-I)-Based Therapeutic Strategies in Acute Myeloid Leukemia (AML) Blood. 112: 860-860. DOI: 10.1182/Blood.V112.11.860.860 |
0.559 |
|
| 2008 |
Abrams SL, Steelman LS, Skolosky ML, Ligresti G, Libra M, McCubrey JA. Roles of Raf/MEK/ERK and PI3K/Akt/mTOR Signaling and p53 Pathways on Apoptosis, Drug Resistance and Therapeutic Sensitivity of Early Hematopoietic Precursor Cells Blood. 112: 503-503. DOI: 10.1182/Blood.V112.11.503.503 |
0.496 |
|
| 2008 |
Bäsecke J, Lehmann A, Bergholz U, McCubrey J, Trümper L, Stocking C, Horn S. The Glycogensynthase Kinase 3b (GSK-3β) Is Involved in Leukemic Transformation Blood. 112: 4489-4489. DOI: 10.1182/Blood.V112.11.4489.4489 |
0.53 |
|
| 2008 |
Chiarini F, Fala F, Ricci F, Tazzari P, Astolfi A, Pession A, McCubrey J, Martelli AM. PI-103, a Dual Inhibitor of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin, Has Cytotoxic Activity in T-Cell Acute Lymphoblastic Leukemia Cells: A New Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia. Blood. 112: 1921-1921. DOI: 10.1182/Blood.V112.11.1921.1921 |
0.539 |
|
| 2008 |
Papa V, Tazzari P, Chiarini F, Ricci F, Martinelli G, Bontadini A, McCubrey J, Lindner LH, Eibl H, Martelli AM. Erucylphosphohomocholine, the First Intravenously Applicable Alkylphosphocholine, Induces Cell Cycle Arrest, Apoptosis, and Synergizes with Chemotherapeutic Drugs in Acute Myelogenous Leukemia Cells-a Novel Therapeutic Approach for Leukemia. Blood. 112: 1330-1330. DOI: 10.1182/blood.v112.11.1330.1330 |
0.465 |
|
| 2007 |
Lehmann BD, McCubrey JA, Terrian DM. Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway. Cancer Biology & Therapy. 6: 1165-70. PMID 18059157 DOI: 10.4161/Cbt.6.8.4544 |
0.356 |
|
| 2007 |
Martelli AM, Tazzari PL, Evangelisti C, Chiarini F, Blalock WL, Billi AM, Manzoli L, McCubrey JA, Cocco L. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Current Medicinal Chemistry. 14: 2009-23. PMID 17691943 DOI: 10.2174/092986707781368423 |
0.736 |
|
| 2007 |
Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, Ciuffreda L, Cognetti F, Tafuri A, Milella M. Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 10: 81-100. PMID 17482503 DOI: 10.1016/J.Drup.2007.03.003 |
0.491 |
|
| 2007 |
Lambert PJ, Shahrier AZ, Whitman AG, Dyson OF, Reber AJ, McCubrey JA, Akula SM. Targeting the PI3K and MAPK pathways to treat Kaposi's-sarcoma-associated herpes virus infection and pathogenesis. Expert Opinion On Therapeutic Targets. 11: 589-99. PMID 17465719 DOI: 10.1517/14728222.11.5.589 |
0.52 |
|
| 2007 |
McCubrey JA, Steelman LS, Franklin RA, Abrams SL, Chappell WH, Wong EW, Lehmann BD, Terrian DM, Basecke J, Stivala F, Libra M, Evangelisti C, Martelli AM. Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. Advances in Enzyme Regulation. 47: 64-103. PMID 17382374 DOI: 10.1016/J.Advenzreg.2006.12.013 |
0.343 |
|
| 2007 |
Tazzari PL, Tabellini G, Bortul R, Papa V, Evangelisti C, Grafone T, Martinelli G, McCubrey JA, Martelli AM. The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia. 21: 886-96. PMID 17361225 DOI: 10.1038/sj.leu.2404643 |
0.368 |
|
| 2007 |
Lehmann BD, McCubrey JA, Jefferson HS, Paine MS, Chappell WH, Terrian DM. A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. Cell Cycle (Georgetown, Tex.). 6: 595-605. PMID 17351335 DOI: 10.4161/Cc.6.5.3901 |
0.391 |
|
| 2007 |
Franklin RA, McCubrey JA. Polyphenols in breast cancer treatment. Cancer Biology & Therapy. 6: 62-3. PMID 17224638 DOI: 10.4161/Cbt.6.1.3676 |
0.348 |
|
| 2007 |
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica Et Biophysica Acta. 1773: 1263-84. PMID 17126425 DOI: 10.1016/J.Bbamcr.2006.10.001 |
0.484 |
|
| 2007 |
Horn S, McCubrey JA, Stocking C, Trumper L, Basecke J. Mutations in the Catalytic Subunit of Class IA PI3K Are Leukemogenic In Vivo. Blood. 110: 875-875. DOI: 10.1182/Blood.V110.11.875.875 |
0.542 |
|
| 2007 |
Abrams SL, Evangelisti C, Chiarini F, Misaghian N, Basecke J, Millela M, Tafuri A, Libra M, Stivala F, Konopleva M, Andreeff M, Steelman LS, Troppmair J, Martelli AM, McCubrey JA. Roles of Raf/MEK/ERK and PI3K/Akt/mTOR Pathways in Prevention of Apoptosis and Induction of Drug Resistance in Myeloid Hematopoietic Cells. Blood. 110: 641-641. DOI: 10.1182/Blood.V110.11.641.641 |
0.494 |
|
| 2007 |
Milella M, Chiaretti S, Ricciardi MR, Tavolaro S, Ciuffreda L, Benassi B, Bellacosa A, Peluso G, Bergamo P, McCubrey JA, Cognetti F, Zupi G, Foà R, Tafuri A. Comparative Gene Profiling of Acute Myeloid Leukemia (AML) and Malignant Melanoma (MEL) Cell Lines Exposed to the MEK Inhibitor PD0325901 Reveals Common Effectors of the MEK/ERK Kinase Module. Blood. 110: 3470-3470. DOI: 10.1182/Blood.V110.11.3470.3470 |
0.41 |
|
| 2007 |
Martelli AM, Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM, Evangelisti C, Abrams SL, Ottaviani E, Martinelli G, McCubrey JA. The Novel Akt Inhibitor Perifosine Induces Apoptosis, Cell Cycle Arrest and Synergizes with Chemotherapeutic Drugs in Acute Myelogenous Leukemia Cells by a JNK Dependent Mechanism - A Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling. Blood. 110: 3355-3355. DOI: 10.1182/Blood.V110.11.3355.3355 |
0.581 |
|
| 2007 |
McCubrey JA, Blalock WL, Tazzari PL, Cappellini A, Iacobucci I, Chiarini F, Abrams SL, Ottaviani E, Martinelli G, Tafuri A, Cocco L, Martelli AM, Fala F. The AKT Inhibitor, A443654, Induces Cell Cycle Arrest, Apoptosis and Synergizes with Chemotherapeutic Drugs in Multi-Drug Resistant T-Cell Acute Lymphoblastic Leukemia - A Novel Agent for Therapy of Drug Resistant ALL. Blood. 110: 3344-3344. DOI: 10.1182/Blood.V110.11.3344.3344 |
0.715 |
|
| 2007 |
McCubrey JA, Bertrand FE, Steelman LS, Chang F, Terrian DM, Franklin RA. Critical roles of the Raf/MEK/ERK pathway in apoptosis and drug resistance Apoptosis, Cell Signaling, and Human Diseases. 2: 101-134. DOI: 10.1007/978-1-59745-199-4_5 |
0.425 |
|
| 2006 |
Garcia R, Franklin RA, McCubrey JA. EGF induces cell motility and multi-drug resistance gene expression in breast cancer cells. Cell Cycle (Georgetown, Tex.). 5: 2820-6. PMID 17172846 DOI: 10.4161/Cc.5.23.3535 |
0.524 |
|
| 2006 |
Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, ... ... McCubrey J, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 10: 375-88. PMID 17097560 DOI: 10.1016/J.Ccr.2006.10.006 |
0.507 |
|
| 2006 |
Franklin RA, Rodriguez-Mora OG, Lahair MM, McCubrey JA. Activation of the calcium/calmodulin-dependent protein kinases as a consequence of oxidative stress. Antioxidants & Redox Signaling. 8: 1807-17. PMID 16987033 DOI: 10.1089/Ars.2006.8.1807 |
0.453 |
|
| 2006 |
McCubrey JA, Lahair MM, Franklin RA. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxidants & Redox Signaling. 8: 1775-89. PMID 16987031 DOI: 10.1089/Ars.2006.8.1775 |
0.411 |
|
| 2006 |
Lahair MM, Howe CJ, Rodriguez-Mora O, McCubrey JA, Franklin RA. Molecular pathways leading to oxidative stress-induced phosphorylation of Akt. Antioxidants & Redox Signaling. 8: 1749-56. PMID 16987028 DOI: 10.1089/Ars.2006.8.1749 |
0.403 |
|
| 2006 |
McCubrey JA, Franklin RA. Reactive oxygen intermediates and signaling through kinase pathways. Antioxidants & Redox Signaling. 8: 1745-8. PMID 16987027 DOI: 10.1089/Ars.2006.8.1745 |
0.391 |
|
| 2006 |
Garcia R, Franklin RA, McCubrey JA. Cell death of MCF-7 human breast cancer cells induced by EGFR activation in the absence of other growth factors. Cell Cycle (Georgetown, Tex.). 5: 1840-6. PMID 16861904 DOI: 10.4161/Cc.5.16.3016 |
0.515 |
|
| 2006 |
Rodriguez-Mora OG, Lahair MM, Evans MJ, Kovacs CJ, Allison RR, Sibata CH, White KS, McCubrey JA, Franklin RA. Inhibition of the CaM-kinases augments cell death in response to oxygen radicals and oxygen radical inducing cancer therapies in MCF-7 human breast cancer cells. Cancer Biology & Therapy. 5: 1022-30. PMID 16855386 DOI: 10.4161/Cbt.5.8.2910 |
0.484 |
|
| 2006 |
McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance Advances in Enzyme Regulation. 46: 249-279. PMID 16854453 DOI: 10.1016/J.Advenzreg.2006.01.004 |
0.8 |
|
| 2006 |
Libra M, Malaponte G, Bevelacqua V, Siciliano R, Castrogiovanni P, Fulvi A, Micali G, Ligresti G, Mazzarino MC, Stivala F, Travali S, McCubrey JA. Absence of BRAF gene mutation in non-melanoma skin tumors. Cell Cycle (Georgetown, Tex.). 5: 968-70. PMID 16687919 DOI: 10.4161/Cc.5.9.2724 |
0.303 |
|
| 2006 |
McCubrey JA, Lahair MM, Franklin RA. OSU-03012 in the treatment of glioblastoma. Molecular Pharmacology. 70: 437-9. PMID 16675657 DOI: 10.1124/Mol.106.026252 |
0.464 |
|
| 2006 |
Bertrand FE, Steelman LS, Chappell WH, Abrams SL, Shelton JG, White ER, Ludwig DL, McCubrey JA. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Leukemia. 20: 1254-60. PMID 16642049 DOI: 10.1038/Sj.Leu.2404217 |
0.676 |
|
| 2006 |
Malaponte G, Libra M, Gangemi P, Bevelacqua V, Mangano K, D'Amico F, Mazzarino MC, Stivala F, McCubrey JA, Travali S. Detection of BRAF gene mutation in primary choroidal melanoma tissue. Cancer Biology & Therapy. 5: 225-7. PMID 16410717 DOI: 10.4161/Cbt.5.2.2429 |
0.323 |
|
| 2006 |
Milella M, Ricciardi MR, Gregorj C, De Cave F, Abrams SL, Steelman LS, Chiaretti S, Konopleva M, Petrucci MT, Cognetti F, Foa R, Andreeff M, McCubrey J, Tafuri A. Molecular and Functional Effects of the Novel MEK Inhibitor PD0325901 in Preclinical Models of Human Leukemias. Blood. 108: 254-254. DOI: 10.1182/Blood.V108.11.254.254 |
0.461 |
|
| 2006 |
Horn S, McCubrey J, Stocking C, Truemper L, Basecke J. Mutations of the Catalytic Subunit of Class IA PI3K Are Constitutively Active and Confer Factor-Independent Growth to Early Hematopoietic Cells. Blood. 108: 1455-1455. DOI: 10.1182/Blood.V108.11.1455.1455 |
0.523 |
|
| 2006 |
McCubrey JA, Abrams SL, Steelman LS, Wong EWT, Chappell WH, Basecke J, Stivala F, Libra M, Milella M, Tafuri A, Troppmair J, Konopleva M, Andreeff M, Evangelisti C, Martelli AM. Dominant Role of Raf/MEK/ERK Signaling in Hematopoietic Cell Cycle Progression, Prevention of Apoptosis and Drug Resistance. Blood. 108: 1116-1116. DOI: 10.1182/Blood.V108.11.1116.1116 |
0.518 |
|
| 2006 |
Thakore CU, Lehmann BD, McCubrey JA, Terrian DM. Intracellular Signaling in Cancer Reviews in Cell Biology and Molecular Medicine. DOI: 10.1002/3527600906.Mcb.200400106 |
0.467 |
|
| 2005 |
Franklin RA, Libra M, Stivala F, McCubrey JA. Two targets are better than one. Promising combination therapy to treat breast cancer. Cancer Biology & Therapy. 4: 1190-1. PMID 16322681 DOI: 10.4161/Cbt.4.11.2335 |
0.305 |
|
| 2005 |
Konopleva M, Shi Y, Steelman LS, Shelton JG, Munsell M, Marini F, McQueen T, Contractor R, McCubrey JA, Andreeff M. Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells. Cancer Research. 65: 9962-70. PMID 16267021 DOI: 10.1158/0008-5472.Can-05-1068 |
0.756 |
|
| 2005 |
Asano T, Yao Y, Shin S, McCubrey J, Abbruzzese JL, Reddy SA. Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells. Cancer Research. 65: 9164-8. PMID 16230374 DOI: 10.1158/0008-5472.Can-05-0779 |
0.492 |
|
| 2005 |
Navolanic PM, McCubrey JA. Pharmacological breast cancer therapy (review). International Journal of Oncology. 27: 1341-4. PMID 16211230 DOI: 10.3892/Ijo.27.5.1341 |
0.71 |
|
| 2005 |
Shelton JG, Steelman LS, Abrams SL, Bertrand FE, Franklin RA, McMahon M, McCubrey JA. The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it? Expert Opinion On Therapeutic Targets. 9: 1009-30. PMID 16185155 DOI: 10.1517/14728222.9.5.1009 |
0.715 |
|
| 2005 |
Ford PW, Hamden KE, Whitman AG, Bryan BA, Chintalgattu V, McCubrey JA, Dyson OF, Akula SM. Cigarette smoke concentrate inhibits Kaposi's sarcoma-associated herpesvirus infection. Virus Research. 114: 172-6. PMID 16105704 DOI: 10.1016/J.Virusres.2005.06.011 |
0.329 |
|
| 2005 |
Libra M, Malaponte G, Navolanic PM, Gangemi P, Bevelacqua V, Proietti L, Bruni B, Stivala F, Mazzarino MC, Travali S, McCubrey JA. Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle (Georgetown, Tex.). 4: 1382-4. PMID 16096377 DOI: 10.4161/Cc.4.10.2026 |
0.682 |
|
| 2005 |
Chappell WH, Green TD, Spengeman JD, McCubrey JA, Akula SM, Bertrand FE. Increased protein expression of the PTEN tumor suppressor in the presence of constitutively active Notch-1. Cell Cycle (Georgetown, Tex.). 4: 1389-95. PMID 16096376 DOI: 10.4161/Cc.4.10.2028 |
0.534 |
|
| 2005 |
Rodriguez-Mora O, LaHair MM, Howe CJ, McCubrey JA, Franklin RA. Calcium/calmodulin-dependent protein kinases as potential targets in cancer therapy. Expert Opinion On Therapeutic Targets. 9: 791-808. PMID 16083343 DOI: 10.1517/14728222.9.4.791 |
0.502 |
|
| 2005 |
McCubrey JA, Bertrand FE. Upping the bid on engineered inducible cell death. Cancer Biology & Therapy. 4: 537. PMID 15970693 DOI: 10.4161/Cbt.4.5.1863 |
0.313 |
|
| 2005 |
Rodriguez-Mora OG, LaHair MM, McCubrey JA, Franklin RA. Calcium/calmodulin-dependent kinase I and calcium/calmodulin-dependent kinase kinase participate in the control of cell cycle progression in MCF-7 human breast cancer cells. Cancer Research. 65: 5408-16. PMID 15958590 DOI: 10.1158/0008-5472.Can-05-0271 |
0.478 |
|
| 2005 |
Shelton JG, Steelman LS, Abrams SL, White ER, Akula SM, Franklin RA, Bertrand FE, McMahon M, McCubrey JA. Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines. Cell Cycle (Georgetown, Tex.). 4: 822-30. PMID 15917660 DOI: 10.4161/Cc.4.6.1724 |
0.742 |
|
| 2005 |
Rodriguez-Mora OG, Howe CJ, Lahair MM, McCubrey JA, Franklin RA. Inhibition of CREB transcriptional activity in human T lymphocytes by oxidative stress. Free Radical Biology & Medicine. 38: 1653-61. PMID 15917193 DOI: 10.1016/J.Freeradbiomed.2005.02.035 |
0.336 |
|
| 2005 |
Shelton JG, Steelman LS, Abrams SL, White ER, Akula SM, Bertrand FE, Franklin RA, McCubrey JA. Effects of endogenous epidermal growth factor receptor signaling on DNA synthesis and ERK activation in a cytokine-dependent hematopoietic cell line. Cell Cycle (Georgetown, Tex.). 4: 818-21. PMID 15908804 DOI: 10.4161/Cc.4.6.1723 |
0.758 |
|
| 2005 |
Demidenko ZN, Halicka D, Kunicki J, McCubrey JA, Darzynkiewicz Z, Blagosklonny MV. Selective killing of adriamycin-resistant (G2 checkpoint-deficient and MRP1-expressing) cancer cells by docetaxel Cancer Research. 65: 4401-4407. PMID 15899832 DOI: 10.1158/0008-5472.Can-04-4428 |
0.476 |
|
| 2005 |
Lee JT, Steelman LS, McCubrey JA. Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cells. International Journal of Oncology. 26: 1637-44. PMID 15870880 |
0.303 |
|
| 2005 |
Demidenko ZN, An WG, Lee JT, Romanova LY, McCubrey JA, Blagosklonny MV. Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin. Cancer Biology & Therapy. 4: 484-90. PMID 15846067 DOI: 10.4161/Cbt.4.4.1702 |
0.438 |
|
| 2005 |
Contractor R, Samudio IJ, Estrov Z, Harris D, McCubrey JA, Safe SH, Andreeff M, Konopleva M. A novel ring-substituted diindolylmethane,1,1-bis[3'-(5-methoxyindolyl)]-1-(p-t-butylphenyl) methane, inhibits extracellular signal-regulated kinase activation and induces apoptosis in acute myelogenous leukemia. Cancer Research. 65: 2890-8. PMID 15805291 DOI: 10.1158/0008-5472.Can-04-3781 |
0.525 |
|
| 2005 |
Akula SM, Ford PW, Whitman AG, Hamden KE, Bryan BA, Cook PP, McCubrey JA. B-Raf-dependent expression of vascular endothelial growth factor-A in Kaposi sarcoma-associated herpesvirus-infected human B cells. Blood. 105: 4516-22. PMID 15705790 DOI: 10.1182/Blood-2004-09-3683 |
0.422 |
|
| 2005 |
Spengeman JD, Green TD, McCubrey JA, Bertrand FE. Activated EGFR promotes the survival of B-lineage acute leukemia in the absence of stromal cells. Cell Cycle (Georgetown, Tex.). 4: 483-7. PMID 15701973 DOI: 10.4161/Cc.4.3.1533 |
0.521 |
|
| 2005 |
Calfee MW, Shelton JG, McCubrey JA, Pesci EC. Solubility and bioactivity of the Pseudomonas quinolone signal are increased by a Pseudomonas aeruginosa-produced surfactant. Infection and Immunity. 73: 878-82. PMID 15664929 DOI: 10.1128/Iai.73.2.878-882.2005 |
0.704 |
|
| 2005 |
Bertrand FE, Spengemen JD, Shelton JG, McCubrey JA. Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support. Leukemia. 19: 98-102. PMID 15496972 DOI: 10.1038/Sj.Leu.2403560 |
0.762 |
|
| 2005 |
Hamden KE, Whitman AG, Ford PW, Shelton JG, McCubrey JA, Akula SM. Raf and VEGF: emerging therapeutic targets in Kaposi's sarcoma-associated herpesvirus infection and angiogenesis in hematopoietic and nonhematopoietic tumors. Leukemia. 19: 18-26. PMID 15470486 DOI: 10.1038/Sj.Leu.2403532 |
0.644 |
|
| 2005 |
Lee JT, McCubrey JA. Targeting the Raf kinase cascade in cancer therapy--novel molecular targets and therapeutic strategies. Expert Opinion On Therapeutic Targets. 6: 659-78. PMID 12472379 DOI: 10.1517/14728222.6.6.659 |
0.494 |
|
| 2005 |
Lee JT, Steelman LS, McCubrey JA. Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cells. International Journal of Oncology. 26: 1637-1644. DOI: 10.3892/Ijo.26.6.1637 |
0.485 |
|
| 2005 |
Libra M, Mazzarino MC, De Re V, Steelman LS, Abrams SL, Bertrand FE, Shelton JG, Molton S, McMahon M, McCubrey JA. Role of BRAF Mutations in Hematopoietic Malignancies and the Induction of Cytokine-Independence-Synergy with PI3K/Akt Pathway. Blood. 106: 4291-4291. DOI: 10.1182/Blood.V106.11.4291.4291 |
0.74 |
|
| 2005 |
Zhang W, Konopleva M, McQueen T, Cortes J, McCubrey J, Andreeff M. Raf Inhibitor BAY 43-9006 Induces Bim Dephosphorylation and Activates the Intracellular Apoptotic Pathway in AML. Blood. 106: 3367-3367. DOI: 10.1182/Blood.V106.11.3367.3367 |
0.545 |
|
| 2005 |
Andreeff M, Contractor R, Ruvolo PP, Deng X, Samudio I, Shi Y, McQueen T, Wang R, Schober W, Ling X, Marini FC, Harris D, Estrov Z, McCubrey J, May WS, et al. Mechanisms of Apoptosis Induction by BH3 Inhibitor ABT-737 in AML. Blood. 106: 244-244. DOI: 10.1182/Blood.V106.11.244.244 |
0.513 |
|
| 2005 |
Abrams SL, Steelman LS, Shelton JG, Chappell WH, Wong EW, Bertrand FE, McCubrey JA. Key Roles of the Raf-1 and Akt in Drug Resistance, Cell Cycle Progression and the Prevention of Apoptosis in Hematopoietic Cells. Blood. 106: 1356-1356. DOI: 10.1182/Blood.V106.11.1356.1356 |
0.779 |
|
| 2004 |
Steelman LS, Bertrand FE, McCubrey JA. The complexity of PTEN: mutation, marker and potential target for therapeutic intervention. Expert Opinion On Therapeutic Targets. 8: 537-50. PMID 15584861 DOI: 10.1517/14728222.8.6.537 |
0.46 |
|
| 2004 |
Lee JT, Steelman LS, McCubrey JA. Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Research. 64: 8397-404. PMID 15548710 DOI: 10.1158/0008-5472.Can-04-1612 |
0.488 |
|
| 2004 |
Hamden KE, Ford PW, Whitman AG, Dyson OF, Cheng SY, McCubrey JA, Akula SM. Raf-induced vascular endothelial growth factor augments Kaposi's sarcoma-associated herpesvirus infection. Journal of Virology. 78: 13381-90. PMID 15542692 DOI: 10.1128/Jvi.78.23.13381-13390.2004 |
0.344 |
|
| 2004 |
Knostman KA, Cho JY, Ryu KY, Lin X, McCubrey JA, Hla T, Liu CH, Di Carlo E, Keri R, Zhang M, Hwang DY, Kisseberth WC, Capen CC, Jhiang SM. Signaling through 3',5'-cyclic adenosine monophosphate and phosphoinositide-3 kinase induces sodium/iodide symporter expression in breast cancer. The Journal of Clinical Endocrinology and Metabolism. 89: 5196-203. PMID 15472226 DOI: 10.1210/Jc.2004-0907 |
0.405 |
|
| 2004 |
Wu D, Thakore CU, Wescott GG, McCubrey JA, Terrian DM. Integrin signaling links protein kinase Cepsilon to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells. Oncogene. 23: 8659-72. PMID 15467757 DOI: 10.1038/Sj.Onc.1207900 |
0.472 |
|
| 2004 |
McCubrey JA, Shelton JG, Steelman LS, Franklin RA, Sreevalsan T, McMahon M. Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells. Oncogene. 23: 7810-20. PMID 15361836 DOI: 10.1038/Sj.Onc.1208055 |
0.761 |
|
| 2004 |
Howe CJ, Lahair MM, McCubrey JA, Franklin RA. Redox regulation of the calcium/calmodulin-dependent protein kinases. The Journal of Biological Chemistry. 279: 44573-81. PMID 15294913 DOI: 10.1074/Jbc.M404175200 |
0.434 |
|
| 2004 |
Ford PW, Hamden KE, Whitman AG, McCubrey JA, Akula SM. Vascular endothelial growth factor augments human herpesvirus-8 (HHV-8/KSHV) infection. Cancer Biology & Therapy. 3: 876-81. PMID 15254407 DOI: 10.4161/Cbt.3.9.1054 |
0.324 |
|
| 2004 |
Akula SM, Ford PW, Whitman AG, Hamden KE, Shelton JG, McCubrey JA. Raf promotes human herpesvirus-8 (HHV-8/KSHV) infection. Oncogene. 23: 5227-41. PMID 15122343 DOI: 10.1038/Sj.Onc.1207643 |
0.721 |
|
| 2004 |
Shelton JG, Blalock WL, White ER, Steelman LS, McCubrey JA. Ability of the activated PI3K/Akt oncoproteins to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells. Cell Cycle (Georgetown, Tex.). 3: 503-12. PMID 15004527 DOI: 10.4161/Cc.3.4.813 |
0.855 |
|
| 2004 |
Navolanic PM, Akula SM, McCubrey JA. Neosis and its potential role in cancer development and chemoresistance. Cancer Biology & Therapy. 3: 219-20. PMID 14752274 DOI: 10.4161/Cbt.3.2.750 |
0.711 |
|
| 2004 |
Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia. 18: 189-218. PMID 14737178 DOI: 10.1038/Sj.Leu.2403241 |
0.85 |
|
| 2004 |
Shelton JG, Steelman LS, White ER, McCubrey JA. Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. Cell Cycle (Georgetown, Tex.). 3: 372-9. PMID 14726697 DOI: 10.4161/Cc.3.3.747 |
0.774 |
|
| 2004 |
Shelton JG, Chang F, Lee JT, Franklin RA, Steelman LS, McCubrey JA. B-raf and insulin synergistically prevent apoptosis and induce cell cycle progression in hematopoietic cells. Cell Cycle (Georgetown, Tex.). 3: 189-96. PMID 14712088 DOI: 10.4161/Cc.3.2.624 |
0.729 |
|
| 2004 |
Whitman AG, Hamden KE, Ford PW, McCubrey JA, Akula SM. Role for Raf in the entry of viruses associated with AIDS (Review) International Journal of Oncology. 25: 469-480. DOI: 10.3892/Ijo.25.2.469 |
0.302 |
|
| 2004 |
Shelton JG, Steelman LS, McMahon M, McCubrey JA. Effects of EGF-R on Transcription Factor Activation in Hematopoietic Cells: EGF-R Activates Multiple Transcription Factors Which Induce Proliferation in the Absence of Autocrine Cytokines. Blood. 104: 4185-4185. DOI: 10.1182/Blood.V104.11.4185.4185 |
0.753 |
|
| 2004 |
Contractor R, Samudio IJ, Estrov Z, Harris D, McCubrey JA, Safe SH, Andreeff M, Konopleva M. A Novel Ring-Substituted Diindolylmethane 1,1-bis [3′-(5-methoxyindolyl)]-1-(p-t-butylphenyl) Methane Abrogates ERK Activation and Induces Apoptosis in Acute Myeloid Leukemia (AML). Blood. 104: 3399-3399. DOI: 10.1182/Blood.V104.11.3399.3399 |
0.499 |
|
| 2004 |
Shelton JG, Steelman LS, McMahon M, McCubrey JA. Effects of EGF-R on Signal Transduction and Anti-Apoptotic Cascades in Hematopoietic Cells: EGF-R Activates Multiple Signal Transduction Cascades Which Result in the Prevention of Apoptosis in the Absence of Autocrine Cytokines. Blood. 104: 1264-1264. DOI: 10.1182/Blood.V104.11.1264.1264 |
0.767 |
|
| 2003 |
Navolanic PM, Lee JT, McCubrey JA. Docetaxel cytotoxicity is enhanced by inhibition of the Raf/MEK/ERK signal transduction pathway. Cancer Biology & Therapy. 2: 677-8. PMID 14688475 DOI: 10.4161/Cbt.2.6.535 |
0.788 |
|
| 2003 |
Rodriguez-Mora O, Franklin RA, McCubrey JA. A new hope for treatment of glioblastomas. Cancer Biology & Therapy. 2: 354-5. PMID 14508104 DOI: 10.4161/Cbt.2.4.438 |
0.352 |
|
| 2003 |
Shelton JG, Moye PW, Steelman LS, Blalock WL, Lee JT, Franklin RA, McMahon M, McCubrey JA. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia. 17: 1765-82. PMID 12970777 DOI: 10.1038/Sj.Leu.2403052 |
0.828 |
|
| 2003 |
Carter BZ, Milella M, Tsao T, McQueen T, Schober WD, Hu W, Dean NM, Steelman L, McCubrey JA, Andreeff M. Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia. 17: 2081-9. PMID 12970762 DOI: 10.1038/Sj.Leu.2403113 |
0.484 |
|
| 2003 |
Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, McCubrey JA. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia. 17: 1263-93. PMID 12835716 DOI: 10.1038/Sj.Leu.2402945 |
0.84 |
|
| 2003 |
Blalock WL, Navolanic PM, Steelman LS, Shelton JG, Moye PW, Lee JT, Franklin RA, Mirza A, McMahon M, White MK, McCubrey JA. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia. Leukemia. 17: 1058-67. PMID 12764369 DOI: 10.1038/Sj.Leu.2402925 |
0.855 |
|
| 2003 |
Shelton JG, Steelman LS, Lee JT, Knapp SL, Blalock WL, Moye PW, Franklin RA, Pohnert SC, Mirza AM, McMahon M, McCubrey JA. Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells. Oncogene. 22: 2478-92. PMID 12717425 DOI: 10.1038/Sj.Onc.1206321 |
0.855 |
|
| 2003 |
Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 17: 590-603. PMID 12646949 DOI: 10.1038/Sj.Leu.2402824 |
0.849 |
|
| 2003 |
Navolanic PM, Pui CH, Larson RA, Bishop MR, Pearce TE, Cairo MS, Goldman SC, Jeha SC, Shanholtz CB, Leonard JP, McCubrey JA. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia. 17: 499-514. PMID 12646938 DOI: 10.1038/sj.leu.2402847 |
0.676 |
|
| 2003 |
Davis JM, Navolanic PM, Weinstein-Oppenheimer CR, Steelman LS, Hu W, Konopleva M, Blagosklonny MV, McCubrey JA. Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 1161-70. PMID 12631622 |
0.835 |
|
| 2003 |
Steelman LS, Blalock WL, Wang XY, Moye PW, Lee JT, Shelton JG, Navolanic PM, Davis JM, Knapp SL, Franklin RA, White MK, McCubrey JA. Elucidation of signal transduction pathways by retroviral infection of cells with modified oncogenes. Methods in Molecular Biology (Clifton, N.J.). 218: 221-52. PMID 12616724 DOI: 10.1385/1-59259-356-9:221 |
0.822 |
|
| 2003 |
Steelman LS, Blalock WL, Wang XY, Moye PW, Lee JT, Shelton JG, Navolanic PM, Davis JM, Knapp SL, Franklin RA, White MK, McCubrey JA. Elucidation of signal transduction pathways by transfection of cells with modified oncogenes. Methods in Molecular Biology (Clifton, N.J.). 218: 203-20. PMID 12616723 |
0.792 |
|
| 2003 |
Steelman LS, Blalock WL, Wang XY, Moye PW, Lee JT, Shelton JG, Navolanic PM, Davis JM, Knapp SL, Franklin RA, White MK, McCubrey JA. Fibroblastic, hematopoietic, and hormone responsive epithelial cell lines and culture conditions for elucidation of signal transduction and drug resistance pathways by gene transfer. Methods in Molecular Biology (Clifton, N.J.). 218: 185-201. PMID 12616722 DOI: 10.1385/1-59259-356-9:185 |
0.823 |
|
| 2003 |
Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R, McCubrey JA. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). International Journal of Oncology. 22: 469-80. PMID 12579299 DOI: 10.3892/Ijo.22.3.469 |
0.839 |
|
| 2003 |
Navolanic PM, Steelman LS, McCubrey JA. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). International Journal of Oncology. 22: 237-52. PMID 12527919 DOI: 10.3892/Ijo.22.2.237 |
0.775 |
|
| 2002 |
Weinstein-Oppenheimer CR, Burrows C, Steelman LS, McCubrey JA. The effects of beta-estradiol on Raf activity, cell cycle progression and growth factor synthesis in the MCF-7 breast cancer cell line. Cancer Biology & Therapy. 1: 256-62. PMID 12432273 DOI: 10.4161/Cbt.77 |
0.774 |
|
| 2002 |
Chang F, Steelman LS, McCubrey JA. Raf-induced cell cycle progression in human TF-1 hematopoietic cells. Cell Cycle (Georgetown, Tex.). 1: 220-6. PMID 12429936 |
0.33 |
|
| 2002 |
Saleh OA, Blalock WL, Burrows C, Steelman LS, Doshi PD, McKearn JP, McCubrey JA. Enhanced ability of the progenipoietin-1 to suppress apoptosis in human hematopoietic cells. International Journal of Molecular Medicine. 10: 385-394. PMID 12239583 DOI: 10.3892/Ijmm.10.4.385 |
0.688 |
|
| 2002 |
Howe CJ, LaHair MM, Maxwell JA, Lee JT, Robinson PJ, Rodriguez-Mora O, McCubrey JA, Franklin RA. Participation of the calcium/calmodulin-dependent kinases in hydrogen peroxide-induced Ikappa B phosphorylation in human T lymphocytes. The Journal of Biological Chemistry. 277: 30469-76. PMID 12063265 DOI: 10.1074/Jbc.M205036200 |
0.413 |
|
| 2002 |
Chang F, Steelman LS, McCubrey JA. Raf-Induced Cell Cycle Progression in Human TF-1 Hematopoietic Cells Cell Cycle. 1: 218-224. DOI: 10.4161/Cc.1.3.128 |
0.572 |
|
| 2001 |
Weinstein-Oppenheimer CR, HenrÃquez-Roldán CF, Davis JM, Navolanic PM, Saleh OA, Steelman LS, Franklin RA, Robinson PJ, McMahon M, McCubrey JA. Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 2898-907. PMID 11555608 |
0.823 |
|
| 2001 |
McCubrey JA, Lee JT, Steelman LS, Blalock WL, Moye PW, Chang F, Pearce M, Shelton JG, White MK, Franklin RA, Pohnert SC. Interactions between the PI3K and Raf signaling pathways can result in the transformation of hematopoietic cells. Cancer Detection and Prevention. 25: 375-93. PMID 11531015 |
0.856 |
|
| 2001 |
McCubrey JA, Blalock WL, Saleh O, Pearce M, Burrows C, Steelman LS, Lee JT, Franklin RA, Oberhaus SM, Moye PW, Doshi PD, McKearn JP. Enhanced ability of daniplestim and myelopoietin-1 to suppress apoptosis in human hematopoietic cells. Leukemia. 15: 1203-16. PMID 11480562 DOI: 10.1038/Sj.Leu.2402167 |
0.628 |
|
| 2001 |
Chang F, McCubrey JA. P21(Cip1) induced by Raf is associated with increased Cdk4 activity in hematopoietic cells. Oncogene. 20: 4354-64. PMID 11466616 DOI: 10.1038/Sj.Onc.1204564 |
0.446 |
|
| 2001 |
McCubrey JA, Steelman LS, Blalock WL, Lee JT, Moye PW, Chang F, Pearce M, Shelton JG, White MK, Franklin RA, Pohnert SC. Synergistic effects of pi3k/akt on abrogation of cytokine-dependency induced by oncogenic raf. Advances in Enzyme Regulation. 41: 289-323. PMID 11384752 DOI: 10.1016/S0065-2571(00)00021-2 |
0.811 |
|
| 2001 |
Kiser M, McCubrey JA, Steelman LS, Shelton JG, Ramage J, Alexander RL, Kucera GL, Pettenati M, Willingham MC, Miller MS, Frankel AE. Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice. Leukemia. 15: 814-8. PMID 11368443 DOI: 10.1038/sj.leu.2402084 |
0.666 |
|
| 2001 |
Blalock WL, Pearce M, Chang F, Lee JT, Pohnert SC, Burrows C, Steelman LS, Franklin RA, McMahon M, McCubrey JA. Effects of inducible MEK1 activation on the cytokine dependency of lymphoid cells. Leukemia. 15: 794-807. PMID 11368441 DOI: 10.1038/Sj.Leu.2402109 |
0.841 |
|
| 2001 |
Franklin RA, Atherfold PA, McCubrey JA. Calcium-induced ERK activation in human T lymphocytes occurs via p56(Lck) and CaM-kinase. Molecular Immunology. 37: 675-83. PMID 11164895 DOI: 10.1016/S0161-5890(00)00087-0 |
0.428 |
|
| 2000 |
Weinstein-Oppenheimer CR, Blalock WL, Steelman LS, Chang F, McCubrey JA. The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors. Pharmacology & Therapeutics. 88: 229-79. PMID 11337027 DOI: 10.1016/S0163-7258(00)00085-1 |
0.846 |
|
| 2000 |
Weinstein-Oppenheimer C, Steelman LS, Algate PA, Blalock WL, Burrows C, Hoyle PE, Lee JT, Moye PW, Shelton JG, Franklin R, McCubrey JA. Effects of deregulated Raf activation on integrin, cytokine-receptor expression and the induction of apoptosis in hematopoietic cells. Leukemia. 14: 1921-38. PMID 11069028 DOI: 10.1038/Sj.Leu.2401926 |
0.837 |
|
| 2000 |
Blalock WL, Moye PW, Chang F, Pearce M, Steelman LS, McMahon M, McCubrey JA. Combined effects of aberrant MEK1 activity and BCL2 overexpression on relieving the cytokine dependency of human and murine hematopoietic cells. Leukemia. 14: 1080-96. PMID 10865974 DOI: 10.1038/Sj.Leu.2401793 |
0.721 |
|
| 2000 |
Moye PW, Blalock WL, Hoyle PE, Chang F, Franklin RA, Weinstein-Oppenheimer C, Pearce M, Steelman L, McMahon M, McCubrey JA. Synergy between Raf and BCL2 in abrogating the cytokine dependency of hematopoietic cells. Leukemia. 14: 1060-79. PMID 10865973 DOI: 10.1038/Sj.Leu.2401792 |
0.837 |
|
| 2000 |
McCubrey JA, Steelman LS, Moye PW, Hoyle PE, Weinstein-Oppenheimer C, Chang F, Pearce M, White MK, Franklin R, Blalock WL. Effects of deregulated RAF and MEK1 expression on the cytokine-dependency of hematopoietic cells. Advances in Enzyme Regulation. 40: 305-37. PMID 10828357 DOI: 10.1016/S0065-2571(99)00033-3 |
0.823 |
|
| 2000 |
Hoyle PE, Moye PW, Steelman LS, Blalock WL, Franklin RA, Pearce M, Cherwinski H, Bosch E, McMahon M, McCubrey JA. Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism. Leukemia. 14: 642-56. PMID 10764150 DOI: 10.1038/Sj.Leu.2401720 |
0.727 |
|
| 2000 |
Blalock WL, Pearce M, Steelman LS, Franklin RA, McCarthy SA, Cherwinski H, McMahon M, McCubrey JA. A conditionally-active form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells. Oncogene. 19: 526-36. PMID 10698522 DOI: 10.1038/Sj.Onc.1203337 |
0.752 |
|
| 2000 |
McCubrey J, Blalock W, Pearce M, Steelman L, Moye P, Burrows C, Saleh O, Smith W, Doshi P, McKearn J. Enhanced ability of myelopoietins, dual receptor agonists for human IL-3 and g-csf receptors and the IL-3 receptor agonist, daniplestim, to suppress apoptosis and stimulate cytokine-inducible gene expression Experimental Hematology. 28: 39. DOI: 10.1016/S0301-472X(00)00209-5 |
0.617 |
|
| 1999 |
Blalock WL, Weinstein-Oppenheimer C, Chang F, Hoyle PE, Wang XY, Algate PA, Franklin RA, Oberhaus SM, Steelman LS, McCubrey JA. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Leukemia. 13: 1109-66. PMID 10450743 DOI: 10.1038/Sj.Leu.2401493 |
0.847 |
|
| 1998 |
McCubrey JA, Steelman LS, Hoyle PE, Blalock WL, Weinstein-Oppenheimer C, Franklin RA, Cherwinski H, Bosch E, McMahon M. Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells. Leukemia. 12: 1903-29. PMID 9844921 DOI: 10.1038/Sj.Leu.2401215 |
0.859 |
|
| 1996 |
Steelman LS, Algate PA, Blalock WL, Wang XY, Prevost KD, Hoyle PE, McCubrey JA. Oncogenic effects of overexpression of the interleukin-3 receptor on hematopoietic cells. Leukemia. 10: 528-42. PMID 8642872 |
0.617 |
|
| 1993 |
Buttke TM, McCubrey JA, Owen TC. Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. Journal of Immunological Methods. 157: 233-40. PMID 8423368 DOI: 10.1016/0022-1759(93)90092-L |
0.363 |
|
| 1991 |
Ways D, Qin W, Riddle R, Garris T, Bennett T, Steelman L, McCubrey J. Differential effect of phorbol esters and interleukin-3 on protein kinase C isoform content and kinase activity in the FDC-P1 cell line Blood. 78: 2633-2641. DOI: 10.1182/Blood.V78.10.2633.Bloodjournal78102633 |
0.444 |
|
| 1990 |
McCubrey J, Steelman L, Sandlin G, Riddle R, Ways D. Effects of phorbol esters on an interleukin-3-dependent cell line Blood. 76: 63-72. DOI: 10.1182/Blood.V76.1.63.Bloodjournal76163 |
0.419 |
|
| 1990 |
McCubrey J, Steelman L, Sandlin G, Riddle R, Ways D. Effects of phorbol esters on an interleukin-3-dependent cell line Blood. 76: 63-72. DOI: 10.1182/blood.v76.1.63.bloodjournal76163 |
0.304 |
|
| 1989 |
Buttke TM, Van Cleave S, Steelman L, McCubrey JA. Absence of unsaturated fatty acid synthesis in murine T lymphocytes Proceedings of the National Academy of Sciences of the United States of America. 86: 6133-6137. PMID 2569740 DOI: 10.1073/Pnas.86.16.6133 |
0.316 |
|
| 1989 |
McCubrey JA, Steelman LS, Risser RG, McKearn JP. Structure and expression of the T cell receptor gamma locus in pre-B and early hemopoietic cells. European Journal of Immunology. 19: 2303-8. PMID 2558023 DOI: 10.1002/Eji.1830191219 |
0.373 |
|
| 1985 |
McKearn JP, McCubrey J, Fagg B. Enrichment of hematopoietic precursor cells and cloning of multipotential B-lymphocyte precursors. Proceedings of the National Academy of Sciences of the United States of America. 82: 7414-8. PMID 3933007 DOI: 10.1073/Pnas.82.21.7414 |
0.327 |
|
| 1983 |
McCubrey J, Risser R. Activation of nonexpressed endogenous ecotropic murine leukemia virus by transfection of genomic DNA into embryo cells. Journal of Virology. 45: 950-5. PMID 6300465 DOI: 10.1128/Jvi.45.3.950-955.1983 |
0.322 |
|
| Show low-probability matches. |